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ABSTRACT 
 
Comparison of Gene Expression in Pre-implantation Bovine Embryos Either Injected or 
Transfected with siRNA Targeted Against E-cadherin. (August 2008) 
Carol Bailey McCormick Hanna, B.S., Colorado State University; 
 M.S., Texas A&M University 
Chair of Advisory Committee: Dr. Duane Kraemer 
 
 The ability to create transgenic livestock is a tremendous benefit in scientific 
research for many disciplines including functional genomics, pharmaceutical synthesis 
and development of enhanced production animals.  Transgenes can either be stably or 
transiently expressed to alter gene function and obtain a specifically engineered 
phenotype.  To create a transgenic bovine embryo, genetically altered somatic cells must 
be used in somatic cell nucleus transfer, or early 1-cell embryos (zygotes) must be 
microinjected with plasmid DNA or small interfering RNA (siRNA).  Given the cost and 
skill associated with both methods, a preliminary investigation exploring alternative 
delivery techniques of siRNA (transient expression) into bovine zygotes with a non-
homologous Cy3 labeled siRNA (Cy3-siRNA) was first performed.  It was discovered 
that zygotes injected with more than 50 µmol L
-1
 of Cy3-siRNA fail to form a blastocoel 
and that, although bovine zygotes are not susceptible to chemical transfection, the 
trophectoderm cells of the blastocyst are.  Based on this information, bovine E-cadherin 
gene expression was compared in day 9 blastocysts derived from either injected zygotes 
iv 
(day 1) or transfected blastocysts (day 7) with a Cy3 labeled E-cadherin specific siRNA 
(Cy3-siEcad) to determine 1) if gene suppression in zygotes injected with 25 µmol L
-1
 
Cy3-siEcad continues during embryo development up to hatching, and 2) if blastocysts 
transfected at a ratio of 9:6 with GeneJammer® truly experience gene knock down after 
siRNA transfection capable of maintaining suppression to day 9.  Quantitative PCR 
indicated blastocysts transfected with Cy3-siEcad had a significant 15.3% decrease (P < 
0.05) in E-cadherin mRNA at day 9 compared to the injected zygotes.  Protein 
fluorescence analysis from immunocytochemistry of whole mounted day 9 blastocysts 
revealed injected zygotes accumulated significantly less E-cadherin protein (67.7%) than 
the transfected blastocysts (P < 0.05).  From these data, it can be concluded that although 
siRNA injection may be capable of knocking down gene expression for the first 7 days 
of embryonic development, it does not persist to the hatching stage; however, blastocysts 
transfected at day 7 do express altered gene expression in the trophectoderm which can 
continue through embryonic hatching events. 
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dsRNA Double Stranded RNA 
ES Cells Embryonic Stem Cells 
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CHAPTER I 
INTRODUCTION 
 
The first report describing the creation of a genetically modified animal was in 
1975 (Jaenisch et al. 1975) when pronuclear stage zygotes were injected with foreign 
viral DNA to produce a viable transgenic mouse.  A decade later, in 1985, the crossover 
from laboratory animals to livestock was made with the creation of the first transgenic 
rabbits, sheep and pigs (Hammer et al. 1985), leading the way for the production of  
other modified livestock species including cattle (Kuroiwa et al. 2004), goats (Reggio et 
al. 2001), chickens (Houdebine 2008), and even fish (Lee and Cole 2007) in the years to 
follow.  These events have transformed research methodology, spurring transgenesis to 
become a powerful tool for biotechnological advancement in mammalian species, 
encompassing many fields in both science and medicine.   
 
Applications for transgenic technology  
Functional genomics studies rely heavily on transgenic mice to define gene 
targets and describe their function for translation into human genomics (Silvestri et al. 
2008).  In fact, several institutions have been established to provide researchers with 
specific gene modified mice including the Texas Institute of Genomic Medicine in 
College Station, Texas and The Jackson Laboratory in Bar Harbor, Maine.  These 
transgenic mice are typically produced with a gene of interest knocked out either 
____________ 
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by an induced mutation which prevents gene expression, or by complete deletion of the 
gene.  Phenotypic and sub-cellular differences may be detected which help define 
specific regulatory functions and pathways associated with a particular gene.  
Additionally, knockout mice are created to produce animal models which express 
symptoms analogous to human disorders allowing investigators to develop potential 
therapeutic strategies for disease treatments (Liu et al. 2008). 
Pharming, a process where specific proteins are produced in the mammary 
glands of transgenic animals and purified from the collected milk, has been utilized in  
several species (Niemann and Kues 2007).  Dairy animals such as cattle and goats are 
the most common types of transgenic animals produced due to the substantial yield of a 
single milking (Niemann and Kues 2007; Poirier and Blancho 2008).  Several companies 
have been established which are dedicated to producing pharmed products for 
commercially available therapeutics.  Netherlands based, Pharming, uses transgenic 
cows to produce Rhucin®, a recombinant human C-1 inhibitor, to treat hereditary 
angioedema.  Similarly, GTC Biotherapeutics in Farmington, Massachusetts, uses 
transgenic goats to pharm ATryn®, a recombinant human antithrombin III to treat deep 
vein thrombosis.  In addition to cattle and goats, mice (Nuijens et al. 1997), rabbits 
(Choi et al. 2007), and pigs (Houdebine 2008) have been successfully pharmed by 
commercial businesses to produce transgenic proteins, although their use is not as 
popular.   
In some cases, the genetic modifications expressed in mammary tissues serve to 
benefit the animal.  It has been demonstrated that milk nutrients in transgenic pigs can be 
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modified to include bovine alpha-lactalbumin which  increases the amount of lactose 
available to the piglets during the first 12 days postpartum (Noble et al. 2002).  Piglets 
from these transgenic gilts had more nutrient rich milk available to them, significantly 
increasing their growth and survival rates as compared to control piglets from non-
transgenic gilts.  In cattle, researchers at the USDA inserted a gene from Staphylococcus 
simulans which was designed to be expressed in the tissues of the mammary glands 
(Rexroad et al. 2007).  The gene product enhanced the intramammary resistance to 
Staphylococcus aureus infection and reduced the animal’s susceptibility to mastitis, a 
debilitating condition in the dairy industry.  In both cases, the utilization of transgenic 
animals in a production setting greatly benefited animal health which ultimately may 
translate into an increase in economic gain.  
Substantial progress has been made in the field of xenotransplantation since the 
incorporation of transgenic animals to produce suitable donors for organ xenografting.  
By knocking out the gene for native alpha 1,3-galactosyltransferase in pigs and inserting 
the human gene for alpha 1,2-fucosylosyltransferase, it may be possible to produce  
transgenic porcine models with organs that do not elicit hyperacute rejection in the 
recipient (Prather 2007).  Although this approach has not yet been evaluated in human 
xenotransplant recipients, it is believed that eventually this transgenic strategy has the 
potential to circumvent delayed xenograft rejection events and greatly increase recipient 
survival rates (Ramsoondar et al. 2003).   
Transgenic technology has also been realized as a solution to environmental 
concerns.  Manure based phosphorus pollution into the environment from pig production 
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farms has become a problem.  To address this issue, scientists in Canada have created 
transgenic pigs which carry the gene for the enzyme phytase, expressed in the saliva 
(Golovan et al. 2001).  Phytase allows the pigs to digest the phytate in their diet which 
would otherwise pass undigested into the manure as phytate phosphorus and contribute 
to environmental pollution.  When compared to non-transgenic controls, phytase pigs 
had 75% less phosphorus in their manure and it is expected that these environmentally 
friendly animals will enter the commercial market within the next few years (Niemann 
and Kues 2007). 
 
Transgenic animal development 
By definition, a transgenic animal possesses a segment of foreign DNA 
incorporated into the genome or has undergone genomic modification by artificial 
induction (Melo et al. 2007).  Although there have been many strategies developed, 
transgenesis in the mouse is most commonly accomplished by targeting specific genes in 
pluripotent embryonic stem (ES) cell cultures, and then transferring the transgenic ES 
cells into an unaltered mouse blastocyst (Schindehutte et al. 2005).  The blastocyst is 
then transferred into a recipient female and germline chimeric offspring are produced 
which are successively bred until a homozygous transgenic individual is obtained (Nagy 
et al. 2003).   
However, ES cell cultures are difficult to establish in non-rodent models, 
eliminating the use of these pluripotent cells for gene targeting in most other species 
(Renard et al. 2007).  Furthermore, it has been estimated that performing the necessary 
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multiple breedings in order to acquire the homozygous individual could take up to six 
years in cattle (Yang et al. 2004).  Combined with the expense involved to maintain a 
breeding herd for that length of time, this strategy is not efficient enough to use in 
livestock based scientific research.  However, a strategy was described where serial 
somatic cell nucleus transfer (SCNT) could be utilized with modified differentiated 
somatic cells to create transgenic cattle (Yang et al. 2004).  Although the time to 
produce a homozygous animal was reduced to almost two years, this strategy is not 
preferential for most as it can only be performed in a specialized laboratory setting and is 
dependent on the inefficient process that is SCNT. 
In 1998, a seminal paper was published which defined RNA interference (RNAi) 
for the first time as a technique for knocking down gene expression in Caenorhabditis 
elegans (Fire et al. 1998).  This technology was quickly adapted for research in many 
species because it allowed for direct modification to somatic cells and embryos, and 
alleviated the need for successive breedings to obtain an affected individual.  This ability 
to shorten production time hallmarked RNAi as the reasonably preferred technique to 
generate transgenic livestock models for scientific investigation. 
 
Discovery of RNA interference 
The first actual account of RNAi mediated gene suppression was reported in 
petunias and attributed to the unknown, but DNA methylation or paramutation between 
alleles was suspected (Napoli et al. 1990).  Researchers were attempting to darken petal 
color by over expressing chalcone synthase (CHS), an enzyme responsible for 
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pigmentation, by introducing a chimeric petunia CHS gene.  Instead of a darker violet 
color in the petals, researchers observed an ablation of color which they termed “co-
suppression” and determined the cause to be a decrease in CHS RNA. 
Shortly after the discovery in petunias, researchers introducing homologous 
sequences into the fungus Neurospora crassa were able to reverse albino coloration by 
silencing the al-1 and al-3 genes (Romano and Macion 1992).  However, as with the 
petunia, the gene silencing pathway was not fully understood and the investigators 
termed the phenomenon as “quelling”. 
Finally, eight years after the first report in petunias, Fire et al. 1998 published a 
report in Nature identifying double stranded RNA (dsRNA) as a potent and specific 
inhibitor of gene expression and termed the process “RNA interference”.  The discovery 
of RNAi was serendipitous as the interfering double stranded RNA was actually the 
control in the experiments.  Sense and antisense single stranded RNA (ssRNA) were 
under evaluation to determine the most effective ssRNA configuration to induce gene 
silencing.  However, investigators discovered that the dsRNA control out performed the 
ssRNA sustaining much higher levels of gene suppression leading the investigation to 
eventually determine the structure and delivery of the interfering dsRNA.  Since its 
discovery, RNAi has been incorporated in over 5,400 reports of gene modification 
studies and is widely considered a dependable and powerful tool in transgenic 
technology, encompassing many types of research models including, but not limited to, 
the mouse (Goa and Zhang 2007), rat (Berhanu and Rush 2008), fruit fly (Chen et al. 
2008), cattle (Kobayahshi et al. 2007), zebrafish (Gruber et al. 2005), chicken 
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(Wakamatsu et al. 2007), and even humans (Nakanishi et al. 2008).  In 2006, Drs. 
Andrew Fire and Craig Mello received the Nobel Prize in Medicine and Physiology for 
their discovery and description of siRNAs, thus lending credence to the colossal impact 
RNAi technology has had on science and transgenic research to date.    
 
Pathways of RNAi expression 
 RNAi is a highly conserved evolutionary process which utilizes double stranded 
RNA to induce silencing of specific genes.  Processing of the interfering RNA strands 
can initiate either in the nucleus or the cytoplasm, depending on the configuration and 
source of the RNA.  The most common types of RNA molecules utilized in research are 
small interfering RNA (siRNA) or short hairpin RNA (shRNA), the latter of which is 
based on the structure of the innate RNAi particle, micro RNA (miRNA).  Expression of 
these RNAs can be either transient or stable, depending on the characteristics of the 
target, delivery method, and experimental need.  Additionally, depending on the target 
mRNA, the effects of RNAi may be reversible, irreversible and in some cases lethal.  
 Micro RNA participates in a highly conserved endogenous gene silencing 
pathway found in most species, and has been estimated to be directly involved in about 
90% of gene regulation in humans (Perron and Provost 2008).  Predictions based on 
bioinformatics suggest that miRNA genes constitute roughly 2% of known human genes, 
50% of which are localized to noncoding RNA transcripts or are nested within the 
introns of other coding genes (Perron and Provost 2008; Ross et al. 2007).  In the 
nucleus of a cell, RNA polymerase II transcribes the miRNA DNA sequence to produce 
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primary miRNA (pri-miRNA) which forms long tandem repeats of stem-loop RNA 
structures (Lee et al. 2004) (Figure 1).  The ribonuclease, Drosha, then cleaves off 
individual stem-loop structures roughly 70 nucleotides (nt) in length and makes further 
modifications to form the miRNA precursors, pre-miRNAs (Lee et al. 2002).  After 
formation, pre-miRNAs are shuttled to the cytoplasm by the protein Exportin-5 in what 
is considered the rate limiting event for miRNA guided gene silencing (Yi et al. 2005).  
 
 
 
 
Fig. 1  MicroRNA processing in the nucleus.  Genes encoding miRNA are transcribed 
by RNA polymerase II resulting in stem-loop formation of the pri-miRNA.  Individual 
hairpins are cleaved by the RNase Drosha forming pre-miRNA and shuttled to the 
cytoplasm by Exportin 5.   
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Once in the cytoplasm, another ribonuclease, Dicer, generates about 21-23 nt dsRNA 
fragments now considered mature miRNA duplexes which typically have incomplete 
homology to their target mRNA (Bernstein et al. 2001) (Figure 2).  Mature miRNA are 
loaded into the RNA-induced silencing complex (RISC), guide RISC to the target 
mRNA, and induce translational repression of the sequence (Martinez et al. 2002).  Once 
inhibited, the mRNAs are transported to P-bodies where they are either rescued and 
reincorporated into a translational pathway, or ultimately, are degraded after an 
unspecified period of accumulation (Perron and Provost 2008). 
Originally, post-transcriptional gene silencing (PTGS) mediated by siRNA was 
accomplished by introducing long dsRNA into the cell cytoplasm where the RNase III, 
Dicer, cleaves the long dsRNA into 21-25 nt duplexes to form the siRNA molecule 
(Zamore et al. 2000).  However, in mammalian cells, the long dsRNA can resemble 
foreign viral RNA and elicit interferon-mediated nonspecific gene silencing (Kawasaki 
et al. 2005) activating the protein kinase PKR and initiating an immune response (Gao 
and Zhang 2007).  To circumvent this reaction, synthetic siRNAs 21 nt long, with a 2 nt 
3’ overhang and complete homology to the target mRNA, can be directly produced and 
introduced into the cellular cytoplasm (Elbashir et al. 2001).   Similar to miRNA, siRNA 
are loaded into RISC and identify the endogenous mRNA target (Figure 3).  However, 
unlike miRNA, the complete homology of the siRNA signals degradation of the target 
by the RISC associated enzyme, Argonaute, which catalyzes the cleavage and 
destruction of the mRNA (Faehnie and Joshua-Tor 2007).  siRNAs have become 
exceptionally popular and accessible for functional genomics studies and many 
10 
 
 
 
Fig. 2  MicroRNA processing in the cytoplasm.  Dicer cleaves the loop off pre-miRNA 
to form mature miRNA that loads into RISC and prevents translation of the target 
mRNA sequence.  Inhibited mRNAs are then stored in the P-body until degradation or 
re-circulation.   
 
 
companies such as Ambion, Austin, Texas or Dharmacon, Chicago, Illinois now design 
and produce them as customized research tools.  Furthermore, with an effective 
sequence, siRNAs are able to reduce gene expression in a multitude of cell types by an 
11 
  
 
 
Fig. 3  siRNA processing in the cytoplasm.  Double stranded RNA is cleaved by Dicer 
to form siRNAs which guide RISC to target mRNA for degradation preventing 
translation.   
   
 
average of 75% (Gou et al. 2007) proving it to be a reliable method for research. 
Both miRNA and siRNA typically generate a transient effect in gene suppression, 
however, depending on the method of delivery a third type of RNAi inducing molecule 
known as shRNA, can provide either transient or stable PTGS.  Short hairpin RNAs 
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have been found by some to be more efficient than siRNAs for inducing gene silencing, 
and because they are transcribed from a vector, can be continuously produced in the 
laboratory making them less costly than commercially produced siRNAs (Cheng and 
Chang 2007).  Design and production of synthetic shRNAs incorporates nucleotide 
sequences found in miRNA to promote appropriate folding and loading of the shRNA 
into Dicer.  A typical coding sequence for shRNA includes a common miRNA context 
region at both the 5’ and 3’ ends with a 22 nt sense-mi RNA loop-22 nt antisense 
sequence nestled in between (Figure 4), which when transcribed forms a RNA stem-loop 
structure similar to pre-miRNA (Paddison et al. 2004).  This sequence is inserted into an 
expression vector under a RNA polymerase III promoter and may also include reporting 
sequences for fluorescent proteins or antibiotic resistance used in selection and 
diagnostics. 
   
 
 
 
Fig. 4  RNA coding sequeances for shRNA.  Common miRNA sequences form the 5’ 
and 3’ ends and the loop structure.  Both the sense and antisense strands are included, 
but the antisense strand incorporates with RISC to induce translational silencing.    
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Transient expression of the shRNA requires similar processing as for miRNA 
(Figure 5).  The shRNA vector is delivered to the cellular cytoplasm where the hairpin 
sequence is eventually transcribed in vivo, modified by Dicer to produce siRNA, and 
loaded into RISC for targeted mRNA translational inhibition (Chang et al. 2006).   
 
 
 
 
Fig. 5  shRNA expression plasmid processing. Plasmids containing a shRNA sequence 
are processed similar to miRNA by polymerase II to form pri-miRNA.  Drosha cleaves 
individual pre-miRNAs which are transported to the cytoplasm by Exportin 5.   
 
 
If stable expression of the shRNA is required, specific types of modified virus can be 
utilized to deliver and integrate the shRNA sequence into the host genome.  The most 
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commonly used viral delivery system is the lentivirus, a member of the retroviridae 
family (Park 2007).  Lentiviral vectors used in research are typically modified from the 
HIV-1 backbone sequence, are non-replicative, and capable of infecting both dividing 
and non-dividing cells.  Along with the transfer plasmid containing the shRNA, two 
other plasmids containing the gag/pol and env viral gene sequences are co-transfected 
into human embryonic kidney 293 cells.  The HEK293 cells transcribe the plasmids and 
produce multiple copies of the RNA hairpins and virus specific enzymes necessary for 
host genome integration, package them in the viral envelope, and release the infecting 
particles into the 293 culture medium (Tiscornia et al. 2006).  Virus is collected from the 
medium and  applied to various cell types including somatic cell cultures, oocytes, and 
embryos (Cockrell and Kafri 2007; Pfeifer et al. 2002).  The shRNA sequence is 
integrated into the host genome and constitutively transcribed in the nucleus to produce 
the designed hairpin capable of entering the pre-miRNA processing pathway and 
successfully inducing post-transcriptional gene silencing (Figure 6). 
    
Application for RNAi in livestock 
 Among the various fields of research, RNAi has become a focus for many 
interested in disease pathology, control and treatment. Translational research has 
demonstrated success utilizing small animal models such as rodents or diverse cell 
cultures to create disease models and evaluate RNAi based therapies for HIV, Hepatitis 
C virus, wound repair, angiogenesis, gene specific treatments, and bone related illnesses 
(Bhindi et al. 2007; Cheema et al. 2007; Hadj-Slimane et al. 2007; Li et al. 2007; Pan et 
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al. 2007; Yeung et al. 2007).  However, the advent of RNAi technology has also allowed 
researchers to further explore livestock species as animal models due to the decreased 
production time required to obtain a genetically altered animal compared to more 
traditional methods.   
 
 
 
 
Fig. 6  Lentiviral delivery of shRNA. Viral enzymes for reverse transcription of the 
RNA sequence and integration into the host genome are delivered along with the shRNA 
sequence.  Once integrated the shRNA gene sequence is transcribed and enters the 
miRNA processing pathway.   
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Lentiviral delivery of shRNAs targeted against the prion gene has been used to stably 
transform caprine somatic cell cultures for SCNT (Golding et al. 2006).  The resulting 
conceptus expressed 90% less prion protein than the non-treated conceptus, suggesting 
that future animals generated by this protocol could be resistant to transmissible 
spongiform encephalopathy (TSE), a contagious and sometimes fatal disease in goats.  
Investigators have also begun defining protocols to establish prion knockout models in 
both bovine and ovine model systems using similar lentiviral delivery methods to create 
animals resistant to TSE and scrapie with similar success (Pfeifer et al. 2006; Sutou et 
al. 2007).  New applications of RNAi in livestock research are emerging and as this 
trend continues, it can be expected that reports describing successful development of 
disease models and therapy directives are quickly approaching. 
 
RNAi in ova and pre-implantation embryos 
 Lentivirus mediated delivery is an effective method to induce stable shRNA 
based gene silencing into cloned animals, however it is not a suitable protocol for all 
research scenarios.  The logistics involved to produce a single cloned animal requires 
abundant time, money, and skill, resources which are not available to all laboratories.  
Therefore, using the porcine and bovine models, strategies have been developed to 
directly treat oocytes and early embryos with lentivirus.  Pigs homogenously expressing 
green fluorescent protein (GFP) have been created by injecting lentivirus carrying the 
GFP gene into the perivitelline space of zygotes.  Of the total zygotes injected, 65% 
expressed the transgene and resulting offspring from embryo transfers produced GFP in 
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the germ cells (Hofmann et al. 2003).  Injection of a self-inactivating lentiviral vector 
containing an enhanced GFP reporter in the perivitelline space has been shown to 
successfully infect bovine oocytes and zygotes with 83% and 22%, respectively, 
expressing GFP and giving rise to live transgenic offspring which retained the transgene 
after 5 months of age (Hofmann et al. 2004).  Further studies have shown that successful 
infection of both bovine oocytes and zygotes can also be achieved by compromising the 
zona with laser drilling and co-incubating with lentivirus.  Although there was no 
observable difference in expression rates of the reporter gene (GFP) between 
microinjection below the zona and co-incubation in zygotes (26% and 26%, 
respectively), a greater proportion of subzonal virus injected oocytes expressed the 
transgene (67%) than those which were zona compromised (44%) (Ewerling et al. 
2006).  With all of these protocols in place to produce transgenic livestock through 
lentivirus mediated delivery, it becomes evident that it is a matter of time before farm 
animals are created with sustained knocked down gene expression derived from RNAi.    
 Although lentivirus delivery of RNAi sequences and other transgenes has proven 
successful in livestock species, persistent knock down of mRNA translation may not 
always be desirable for targeting transient or acute temporal gene expression in early 
embryos.  Investigations of functional genomics involving oocyte development, 
embryonic stem cell differentiation, elongation or implantation could benefit from direct 
treatment of the oocytes or embryos with transiently expressed siRNA without the 
requirement of a lentivirus delivery system.  Direct microinjection has been established 
as a useful method for delivery of dsRNA targeted against cyclin B1 into bovine 
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oocytes, although efficient knock down of gene expression has had limited success 
(Paradis et al. 2005). Successful microinjection of dsRNA into bovine zygotes has been 
reported to decrease E-cadherin gene expression by 80% in subsequent blastocysts 
(Nganvongpanit et al. 2006a) but has not been successful in knocking down Connexin-
43 expression (Tesfaye et al. 2007).  However, techniques for efficient delivery of 
siRNA into non-rodent embryos still needs further exploration, and attempts to do so 
with alternate methods in bovine zygotes are discussed in detail in Chapter II.   
 
Experimental design 
 Since it is known that microinjected dsRNA can down regulate E-cadherin in 
bovine embryos up to day 7 in the blastocyst stage, it was decided to use the same target 
to determine if injected siRNA delivered at the zygote stage will persist through 
blastocyst expansion and hatching.  This would make investigations into mechanisms 
such as apoptosis, which can greatly affect implantation and pregnancy rates, during 
hatching and post-hatching events possible (Jousan et al. 2008).  In addition, recent 
studies, detailed in Chapter II, have established chemical transfection as a reliable 
method to deliver siRNA to trophectoderm cells in early blastocysts.  Applying these 
two methods, gene expression of E-cadherin will be compared at day 9 of development 
between injected zygotes versus transfected early blastocysts with siRNA to evaluate 
efficacy of each treatment. 
 To accomplish this experiment, the complete coding sequence for bovine E-
cadherin was first determined so that three different homologous siRNAs could be 
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designed.  Synthesized siRNAs were validated by transfection into a cell culture to 
confirm silencing of the gene product and measured with quantitative PCR and western 
blot densitometry analysis.  Once an effective siRNA was identified, it was injected into 
the cytoplasm of day 1 in vitro produced (IVP) zygotes or transfected into the 
trophectoderm cells of day 7 IVP blastocysts.  On day 9 of development, all embryos 
were collected and E-cadherin expression was measured by quantitative PCR and 
densitometry measurements made from scanning confocal images of 
immunocytochemically labeled embryos (Figure 7).  Comparisons of expression values 
between injected and transfected embryos were made to determine the most effective 
method to knock down gene expression in future post-hatching gene regulation studies. 
 
 
 
Fig. 7  Flow chart of experiments.  IVF was performed on Day 0, followed by two 
independent  embryo treatments at Day 1 or Day 7, and collection of embryos at Day 9. 
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CHAPTER II 
PRELIMINARY INVESTIGATIONS: DELIVERY  
OF TRANSIENTLY EXPRESSED siRNA INTO BOVINE ZYGOTES 
 
 Pronuclear and cytoplasmic microinjection, or direct injection, has been well 
documented as a popular method for delivering transiently expressing foreign 
RNA/DNA into non-rodent oocytes and embryos (Dehennaut et al. 2008; Freitas et al. 
2003; Nganvongpanit et al. 2006b; Verma et al. 2008) and is well established as an 
effective procedure in mouse zygotes to produce transgenic animals (Ittner and Götz 
2007).  Although microinjection is widely used in livestock species, there are limiting 
complications which still make it an inefficient process.  Developmental rates to the 
blastocyst stage are often decreased due to technical error such as injection of too much 
fluid or lysis of the vitelline membrane with the injection pipette.  Embryos of lesser 
quality which would otherwise develop in culture, often cannot recover from these 
insults and degrade in culture leaving only the better quality embryos to develop  (Maga 
et al. 2003; Nganvongpanit et al. 2006a).  In addition, integration before the first round 
of DNA replication or homologous distribution of the transgene throughout the 
cytoplasm does not always occur which can lead to mosaic expression during cell 
division in successively cleaving blastomeres (Rosochacki et al. 2003).  Furthermore, 
successful application of microinjection requires expensive equipment and highly skilled 
technicians.  The oocytes or embryos must be treated individually making the process 
not only expensive, but laborious and time consuming.   
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The initial aim of the research project was to bypass the problems associated with 
microinjection and devise a method to transiently transfect small groups of bovine 
zygotes in one treatment.  Less invasive, grouped methods could eliminate the need for 
expensive equipment, advanced technical skills, limit the embryo treatment time out of 
culture and potentially alleviate the occurrence of chimerism associated with 
microinjection.  Several embryo group treatment approaches to introduce siRNA into 
bovine zygotes were evaluated including chemical transfection, electroporation, and 
chemically induced vitelline membrane pore formation.  Comparisons of transfection 
efficiency and blastocyst development were made for each treatment and ultimately 
compared to the control method of direct injection.   
 
Microinjection 
 Before exploring alternative methods of siRNA delivery, developmental 
hindrance was assessed in bovine zygotes injected with siRNA.  DNA plasmid injection 
has been routinely used in this laboratory to successfully express transgenes into the 
cytoplasm of zygotes.  Therefore developmental rates of zygotes injected with siRNA 
were compared to previous developmental data collected from zygotes injected with  one 
of three plasmids (at a concentration of 50 ng µl
-1
) which possessed either the of 
fluorescent reporter genes, green fluorescent protein (GFP) or red fluorescent protein 
(RFP).  Table 1 indicates that it is possible to obtain transcription of the cytoplasm 
injected transgenes from a plasmid in bovine zygotes, however, our experience is that 
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Table 1.  Three plasmids used for cytoplasmic injection into bovine zygotes.  Cleav %, 
cleavage rates at day 2 post fertilization; Blast %, blastocyst formation rates at day 7; 
Fluor %, percentage of total zygotes with fluorescent blastomeres at day 4 (8-cell).  
*All reported with mosaic expression.  
 Plasmid Reporter 
Expression 
Location 
Emission 
λ nm 
Total # 
Zygotes 
Cleav 
% 
Blast 
 % 
Fluor* 
% 
Control None None None 66 73 20 0 
Fug-W GFP Cytoplasm 509 64 48 8 8 
dsRed RFP Cytoplasm 579 56 35 0 13 
phEFnGFP GFP Nucleus 509 56 45 0 16 
   
 
once the embryos begin to cleave, reporter proteins reveal distribution among the 
blastomeres is unequal resulting in mosaic expression. 
 
Experiment 1 
To monitor delivery of the injected siRNA into zygotes, a Negative Control #1 
siRNA (Cat# AM4621; Ambion, Inc., Austin, Texas) verified by Ambion to be non-
homologous to any know bovine gene sequence was used.  The siRNA was labeled on 
the 5’ end with the red fluorescent dye Cy3 which permitted immediate visual 
confirmation of cytoplasmic delivery of the siRNA into the zygote under fluorescent 
excitation at 547 nm.  This allowed for measurement of transfection efficiency and 
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developmental competence without incurring the expense of gene specific siRNA design 
and gene expression analysis.  
 Bovine zygotes were produced in vitro by standard lab operating procedures and 
cumulus cells were removed by vortexing in 200 µl of warmed TL-Hepes (GIBCO, 
BRL, Rockville, MD) for 2 minutes.  After vortexing, zygotes were washed twice 
through warmed Holding medium consisting of TCM-199 with Hank’s salts (GIBCO, 
BRL) supplemented with 10% v/v fetal bovine serum (FBS; HyClone, Logan, UT) and 
1% gentamicin (50 mg ml
-1
 solution; GIBCO, BRL) and held until injection. 
 Lyophilized Cy3-siRNA was reconstituted to 100 µmol L
-1
 with the supplied 
RNase-DNase free water and then diluted to the desired final concentration in TE buffer 
(Appendix A).  Injection plates were assembled by adding a 20 µl drop of Holding 
medium to the center of a 100 mm round tissue culture dish and a 5 µl drop of diluted 
Cy3-siRNA.  Both drops were overlaid with warmed embryo culture tested light mineral 
oil (Sigma-Aldrich, St. Louis, MO) and ~30 zygotes were pipetted into the Holding 
drop.  Embryos were visualized through a Zeiss Axiovert inverted microscope and held 
in place with a glass holding pipette (outer diameter: 180 – 200 µm, inner diameter: 40 – 
60 µm).  Injection pipettes were made by pulling glass capillary tubes with a Sutter 
Flaming/Brown P-97 puller to a filamentous tip [P=200, Heat=450, Pull=21, Vel=50, 
t=120] which was then broken against the holding pipette in the siRNA drop creating a 
lumen 3- 4 µm in diameter.  Over a series of 2-3 replicates, embryos were injected once 
with 10 – 100 pl (enough to observe slight expansion of the cytoplasm) with one of the 
listed concentrations in Table 2, then washed through G1 (Vitrolife, Inc., Englewood, 
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CO) embryo culture medium supplemented with 8 mg ml
-1
 Pentax BSA (Miles 
Laboratories, Elkhart, IN) and 1 µl ml
-1
 gentamicin and returned to culture in 500 µl 
fresh supplemented G1 for 72 hours at 38°C with 5% CO2, 5% O2, and 90% N2 
humidified air (5/5/90).  In addition to siRNA, some zygotes were injected with TE 
buffer alone to ascertain changes in development due to the actual injection procedure  
 
Table 2.  Development rates and transfection efficiencies of bovine zygotes injected 
with Cy3-siRNA.  Cleav %, cleavage rates at day 2 post fertilization; Blast %, blastocyst 
formation rates at day 7; Fluor %, percentage of total zygotes with fluorescent 
blastomeres at day 4 (8-cell). 
Treatment Concentration 
Total # 
Zygotes Cleav % Blast % Fluor % 
Control None 56 52 23 0 
TE None 55 56 22 0 
Cy3-siRNA 1 nmol L
-1
 33 33 15 0 
Cy3-siRNA 50 nmol L
-1
 31 32 16 0 
Cy3-siRNA 100 nmol L
-1
 57 32 12 4 
Cy3-siRNA 1 µmol L
-1
 55 29 11 9 
Cy3-siRNA 50 µmol L
-1
 69 45 3 41 
Cy3-siRNA 100 µmol L
-1
 26 31 0 19 
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and other zygotes were not injected but rather moved directly into culture to assess the 
control development rates.  After 72 hours, embryos with fluorescent blastomeres were 
recorded and then moved to 500 µl G2 (Vitrolife, Inc., Englewood, CO) similarly 
supplemented with G1 and returned to culture for an additional 72 hours at which point 
blastocyst development rates could be determined. 
 Forty minutes after the initial injections, all treated zygotes were observed under 
fluorescent light.  Red fluorescence was visible in those injected with 100 nmol L
-1 
or 
greater but not in those treated with 1 or 50 nmol L
-1
.  After 3 days in culture, all 
embryos with red fluorescence had homogenous expression among all blastomeres and 
embryos injected with 50 µmol L
-1
 had the largest proportion of fluorescence still visible 
at the 8-cell stage.  The injection process itself was not overtly detrimental to embryo 
development as noted by similar blastocyst formation rates between the control and TE 
injected zygotes.  However, an increase in concentrations of the injected Cy3-siRNA 
resulted in a decrease in blastocyst formation. It is unclear the fate of the Cy3 once in the 
cell and if visual detection correlates to siRNA longevity.  Therefore it is difficult to say 
by the 8-cell stage when fluorescence was evaluated again, if treatments in which there 
was no fluorescence detected was due to degradation of the Cy3 signal alone or if 
siRNAs were also depleted.   
 Given these results, it was determined that 1 - 50 µmol L
-1
 of Cy3-siRNA would 
be appropriate to deliver enough siRNA into bovine zygotes to sustain expression 
through subsequent cell divisions and still produce blastocysts for future gene expression  
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Fig. 8  Zygote microinjection.  Bovine zygotes injected with Cy3-siRNA, A) observed 
with bright field, B) observed under fluorescence, or injected with Fug-W, C) observed 
with bright field, D) observed under fluorescence.  
 
 
analysis studies.  However, appropriate concentrations may vary for individual 
experiments depending on the abundance of the mRNA target.   
 
Experiment 2 
In a final evaluation, a comparison was made between bovine zygotes injected 
with 50 µmol L
-1
 Cy3-siRNA or 50 ng ml
-1
 Fug-W (the single plasmid demonstrated to 
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allow blastocyst development) to compare distribution of the injected transgene.  
Although blastocyst formation was lower in siRNA compared to plasmid treated 
embryos (2% and 9% respectively), 40% of the Cy3-siRNA injected embryos had 
homogenous fluorescence in all blastomeres and only 7% of the Fug-W treated embryos 
expressed GFP in a mosaic pattern (Figure 8). 
 The ability of the siRNA to consistently distribute evenly throughout the 
cytoplasm may be a result of RISC processing the molecule and shuttling it throughout 
the embryo in search of the mRNA target.  Although shRNA transcribed from a plasmid 
are subject to the same distribution as siRNA, entire plasmids are not known to 
participate in any such pathway.  Instead, they are subject to placement where they were 
injected and dependant on cellular metabolism and division events for distribution which 
may account for the mosaic expression often seen with the reporter protein.  Therefore, it 
was concluded that for transient gene suppression studies, siRNAs are preferable to 
plasmid based gene silencing due to homogenous distribution during embryo cleavage.  
Although development is diminished when injected, siRNAs are a possible mechanism 
to induce transient gene silencing for studies in bovine early embryos and an acceptable 
control to compare to when developing other methods of siRNA delivery. 
 
Chemical transfection 
 Chemical transfection is a common method used in both somatic and stem cell 
cultures to successfully introduce foreign RNA/DNA into the cytoplasm (Arnold et al. 
2006; Tinsley et al. 2006; Zhang et al. 2007).  There are numerous commercial kits 
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available for chemical transfections that utilize either cationic liposomes (termed 
lipofection) or cationic polymers.  The cationic lipid based reagents FuGENE 6 (Cat# 
11815091; Roche Applied Science, Indianapolis, IN) and Lipofectamine 2000 (Cat# 
11668-027; Invitrogen, Carlsbad, California) bind the anionic RNA/DN into a liposome 
which then fuses with the eukaryotic cell membrane and passively transports the cargo 
into the cytoplasm.   Cationic polymers such as GeneJammer (Cat# 204130; Stratagene, 
La Jolla, California) and ExGen 500 (Cat# R0511; Fermentas Life Sciences, Glen 
Burnie, Maryland) form an ionic bond with the RNA/DNA and through endocytosis are 
actively transported into the cell. These transfection reagents have all been developed in 
an effort to produce low cytotoxic effects while increasing transfection efficiency on a 
wide variation of cell types.  In addition, preparation time of the RNA/DNA conjugates 
with transfection reagents is rapid and does not require expensive equipment to perform.  
Given the benefits of chemical transfection and the potential to treat many oocytes or 
embryos at one time, the possibility of delivering siRNAs via transfection into zygote 
stage embryos, as opposed to microinjection, was explored. 
There are two reports indicating successful transfection in mouse oocytes and 
embryos using a commercial cationic liposome reagent.  In the earliest report, immature 
oocytes to blastocyst stage embryos with either an intact or permeabilized zona were 
cultured in 50 µl of a plasmid DNA-FuGENE conjugate (125ng DNA-1 µl FuGENE 
diluted in 100 µl medium) for 3 hours (Carballada et al. 2000).  Except for morulae with 
intact zonae, all treated oocytes and embryos exhibited varying degrees of success from 
23.5% to100% positive transfection efficiencies (indicated by plasmid driven GFP 
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fluorescence) and subsequent developmental rates were not significantly different from 
the untreated controls.  In a follow-up report, a DNA plasmid containing the lacz gene 
was successfully transfected into zona compromised murine pronuclear stage embryos 
using FuGENE (as described above) to produce transgenic offspring (Carballada et al. 
2002).  Although the transgene was detected in many tissues and organs in the transgenic 
mice, transfection efficiencies were extremely low and only 1.27% of the treated 
embryos that were transferred, survived.    
 
 
 
 
Fig. 9  Laser drilling a rent through bovine zygote zonae.  A) intact zygote with a 
slightly shrunken membrane and rotated so polar body is not visible, B) target sights 
indicate placement of laser burst, C) first hole in zona has been drilled, D) completed 
drilling through zona with three successive laser bursts. 
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Experiment 3 
Given the success transfecting zygotes in mice, FuGENE was the first 
transfection reagent evaluated at various ratios in co-culture with bovine zygotes for 48 
hours.  To compromise the zona, an objective mounted class I laser (Hamilton Thorne 
Biosciences, Beverly, MA) was used to drill a hole completely penetrating the zona 
(Figure 9).  Cumulus cells were removed as previously described from presumptive 
zygotes which were transferred into 500 µl of warmed Holding medium supplemented 
with 75 mmol L
-1
 sucrose to slightly shrink the perivitelline membrane and reduce the 
risk of nicking the embryo with the laser.  Zonae were drilled at 90% power with a 600 
µsec pulse creating three successive holes, 20 µm in diameter, producing a rent that 
completely transversed the zona pellucida.  After drilling, zygotes were washed twice 
through fresh Holding medium, once through G1, and moved to 450 µl of supplemented 
G1 culture medium (without gentamicin) until use. 
To construct the FuGENE and siRNA conjugate, the specified amount of 
FuGENE was added to G1 (no BSA or gentamicin), mixed well, and allowed to incubate 
at room temperature for 5 minutes (Table 3).  The specified quantity of siRNA (defined 
in Table 3) was then added from a 100 µmol L
-1
 stock solution to the G1, bringing the 
final volume up to 50 µl, held at room temperature for 15 additional minutes before drop 
wise addition to the zygotes in G1 (no gentamicin) while the dish was swirled, 
thoroughly mixing the zygotes with the conjugated transfection compounds.  In addition, 
non-treated, FuGENE only, and Cy3-siRNA only controls were evaluated to determine 
the effects of each on embryo development.  After 48 hours, embryos were moved to 
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fresh supplemented G1 and evaluated for fluorescence.  After an additional  24 hours in 
G1, embryos were moved to supplemented G2 (G1/G2 sequential culture), cultured for 
an additional 72 hours after which blastocyst development rates were obtained.   None of 
the evaluated ratios successfully transfected the embryos as indicated by lack of 
detectable fluorescence at 24 and 48 hours in any of  
 
 Table 3. Experiment 3 blastocyst formation.  Lasered bovine 
zygotes were co-cultured for 48 hours with transfection complex.   
No fluorescence was detected in any of the treatments. 
Treatment FuGENE:siRNA 
Total # 
Zygotes Blastocyst  % 
Control None 21 43 
FuGENE Only 1 µl FuGENE 30 7 
Cy3-siRNA Only 1 µg Cy3-siRNA 30 10 
Transfect 1 µl:125 ng 31 16 
Transfect 1 µl:500 ng 33 18 
Transfect 3 µl:1 µg 36 6 
Transfect 3 µl:2 µg 34 15 
Transfect 6 µl:1 µg 35 9 
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the treatments.  Exposure to FuGENE for 48 hours and use of the laser with sucrose 
appeared to have a negative effect on embryo development as blastocyst rates for all 
treatments (range 7-18%) were noticeable lower than the control (43%).  From these 
data, it was concluded that greater care needed to be taken when drilling the zonae and a 
higher concentration of sucrose should be considered to further shrink the vitelline 
membrane increasing the distance between it and the laser and decreasing the risk of 
damage on the cytoplasm.  Furthermore, it was suspected that 48 hours exposure to 
FuGENE was toxic to the embryos and shorter exposure times warranted evaluation.  
 
Experiment 4 
Similar ratios were evaluated as detailed in Experiment 3, however the sucrose 
concentration in which zygotes were lasered was increased to 200 mmol L
-1
 and zygotes 
were incubated directly in the transfection complexes for 3 hours at 38.5ºC in 5/5/90 
humidified air.  After incubation, zygotes were washed through supplemented G1 and 
cultured in sequential G1/G2 for 6 days.  Fluorescence was evaluated directly after 3 
hours of co-culture with the transfection complex and again after 24 hours.  As observed 
in Experiment 3, none of the treatments successfully transfected the bovine zygotes.  
Blastocyst rates were variable and not overtly attributable to any one factor (Table 4). 
 
Experiment 5 
 Increased concentrations of FuGENE transfection reagent and siRNA were 
evaluated simultaneously with a second lipid based transfection chemical, Lipofectamine 
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2000 (Table 5).  Zygotes were prepared as described in Experiment 2 and treated 
similarly, except incubation in either transfection compound was increased to 4 hours.  
Embryos were evaluated for fluorescence immediately after incubation in the complex 
and again after 24 hours of culture.  After 4 hours, zygotes cultured in a 9 µl:6 µg ratio 
of FuGENE to siRNA obtained 48% fluorescence and in those treated with 12 µl:8 µg, 
4% expressed the Cy3-siRNA throughout the cytoplasm.  However, after 24 hours of  
 
Table 4. Experiment 4 blastocyst formation.  Lasered bovine zygotes 
were incubated in transfection complex for 3 hours.   No 
fluorescence was detected in any of the treatments. 
Treatment FuGENE:siRNA 
Total # 
Zygotes Blastocyst  % 
Control None 24 25 
FuGENE Only 1 µl FuGENE 24 29 
Cy3-siRNA Only 1 µg Cy3-siRNA 26 27 
Transfect 1 µl:125 ng 26 4 
Transfect 1 µl:500 ng 25 20 
Transfect 3 µl:1 µg 25 8 
Transfect 3 µl:2 µg 24 33 
Transfect 6 µl:1 µg 24 4 
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culture in G1, those which previously fluoresced red did not continue to develop and the 
cytoplasm appeared to be in early stages of degeneration and most likely were already 
dead when put into co-culture.  Furthermore, blastocyst formation was ablated at all 
levels tested in FuGENE and in the highest concentration of Lipofectamine.  Based on 
these results, it was decided to continue evaluating delivery methods with FuGENE and 
to reduce the amount used in culture with the zygotes.    
 
 
Table 5. Experiment 5 blastocyst formation and transfection efficiencies.  Lasered 
bovine zygotes were incubated in transfection complex for 4 hours.  Lipofect, 
Lipofectamine 2000.    
Treatment Reagent:siRNA 
Total # 
Zygotes Blastocyst  % 
Fluorescence 
%  At 4 Hours 
Control None 30 17 0 
FuGENE Only 9 µl 21 0 0 
FuGENE Transfect 9 µl:6 µg 25 0 48 
FuGENE Transfect 12 µl:8 µg 28 0 4 
Lipofect Only 9 µl 25 8 0 
Lipofect Transfect 9 µl:6 µg 26 12 0 
Lipofect Transfect 12 µl:8 µg 24 0 0 
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Experiment 6 
 To maintain closer proximity to the cytoplasmic membrane, 100-150 pl of three 
different FuGENE transfection ratios were directly injected into the perivitelline space of 
zona intact zygotes (Table 6).  Additionally, the same ratios were also used to laser the 
zygotes directly in the complex and continuing with 3 hours of co-culture to take 
advantage of any gradient differentials which might force the transfection compound 
into the perivitelline space (Table 6).  After co-culture, all embryos were moved into  
G1/G2 sequential embryo culture for 6 days.  As reported in Experiments 1 and 2, none 
of the treatments produced successful transfection in bovine zygotes following 3 hours 
of culture in transfection complex. 
 
Experiment 7 
 To determine if the rent created by the laser was simply not allowing adequate 
access of FuGENE to the zygotic membrane, zonae were either weakened with acid 
Tyrodes (pH 2.5; Sigma-Aldrich, St. Louis, MO) or completely removed with 0.5% 
Pronase E in Holding medium (Table 7).  For each treatment, cumulus free zygotes were 
transferred to 500 µl of either solution for 3 minutes, then washed three times through 
fresh Holding medium before incubation for 3 hours directly in the FuGENE complex 
with a ratio of 3 µl of FuGENE to 4 µg of Cy3-siRNA.  Neither of the zona treatments 
appeared to have a positive effect on transfection efficiencies as there was no 
fluorescence detected for either method after 3 hours of incubation in transfection 
compound.  Blastocyst formation rates for Pronase E treated embryos was much lower 
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than the control due to recombination of blastomeres from multiple embryos creating 
several giant blastocysts. 
 
Table 6. Experiment 6 blastocyst formation.  Bovine zygote development after 
injection of the transfection complex into the perivitelline space (PVSI) or laser 
drilling of the zonae in the transfection complex (DIC) followed by co-culture for 
3 hours.  
Treatment FuGENE:siRNA 
Total # 
Zygotes Blastocyst  % 
Control None 37 46 
FuGENE Only 3 µl 39 54 
PVSI 1 µl:125 ng 39 41 
PVSI 3 µl:2 ng 36 69 
PVSI 9 µl:6 µg 41 46 
    
Control None 40 23 
FuGENE Only 3 µl 42 14 
DIC 1 µl:125 ng 41 10 
DIC 3 µl:2 ng 40 15 
DIC 9 µl:6 µg 43 7 
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Experiment 8 
 Cumulus free ova were injected subzonally with transfection complex to 
ascertain if the cortical granule envelope which forms around the periphery of the 
ooplasm immediately after fertilization could be preventing successful transfection.  
Cumulus cells were removed by pipetting the ova through a fine bore glass needle and 
100-150 pl of transfection compound was injected beneath the zona.  Ova were 
subjected to standard in vitro fertilization protocols and cultured in sequential G1/G2 
media to the blastocyst stage.  After 24 hours, none of the treated ova exhibited 
fluorescence indicating that the cortical granule envelope may not be the block 
preventing successful transfections of bovine zygotes. Blastocyst rates were also greater 
in the treated oocytes indicating that the micromanipulation, although subtle, may have 
induced parthenogenic activation (Table 8). 
 
Table 7. Experiment 7 blastocyst formation.  Embryo development after zona 
weakening with acid Tyrode’s or zona removal with Pronase E followed by 3 
hours incubation directly in FuGENE transfection complex. 
Treatment FuGENE:siRNA 
Total # 
Zygotes Blastocyst  % 
Control None 50 50 
Acid Tyrode’s 3 µl:4 µg 50 10 
Pronase E 3 µl:4 µg 49 41 
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 Table 8. Experiment 8 blastocyst formation.  Embryo development after 
injection of FuGENE below the zona of cumulus free bovine ova. 
Treatment FuGENE:siRNA 
Total # 
Zygotes Blastocyst  % 
Control None 53 9 
Cumulus Free Control None 52 25 
Cumulus Free FuGENE Only 3 µl 53 23 
Cumulus Free Transfect 3 µl:2 µg 49 35 
 
 
Experiment 9 
 An alternate transfection reagent, ExGen 500, was evaluated in bovine zygotes.  
Different from FuGENE and Lipofectamine 2000, ExGen 500 is a cationic polymer 
which induces active transport of the siRNA across the cell membrane where it becomes 
a proton sponge lysing the endosome and releasing the siRNA before it is transported 
and degraded in a lysosome.  Zygotes were laser drilled in 200 mmol L
-1
 sucrose and 
transferred to 450 µl supplemented G1 (without gentamicin).  The Cy3-siRNA was 
diluted into 50 µl of 150 mmol L
-1
 sodium chloride and vortexed.  ExGen 500 was then 
added and the sample was vortexed for 10 seconds, held at room temperature for 10 
minutes, then applied drop wise to the zygotes in G1.  The following ratios of ExGen 
500 to Cy3-siRNA were evaluated: 1:3, 1:6, 1:9, 2:6, 2:12, and 2:18 as well as non-
treated, laser treated only, and 9 µl of ExGen only controls.  After 24 hours of co-
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culture, not only were there no fluorescence detected in any embryos, but none of the 
embryos treated with ExGen cleaved, unlike the controls without ExGen which had 25 
and 12% cleavage.  Based on these data ExGen was not considered for future 
transfection experiments. 
 
Experiment 10 
 Results from Experiments 3-9 demonstrate the difficulty associated with 
chemically transfecting bovine zygotes, however, it was not known if any developmental 
stage other than zygotes would preferentially take up the transfection regents.  
Therefore, chemical transfection with two different reagents, either FuGENE (lipid 
based) or GeneJammer (cationic polyamine) were tested on ova and with all stages of 
embryo development through blastocyst formation (Table 9).  All ova and embryos were 
laser drilled in 200 mmol L
-1
 sucrose and moved to either 450 µl of TCM-199 with 
Earle’s salts and 10% v/v fetal bovine serum (ova) or supplemented G1 (no gentamicin) 
(embryos).  Transfection complexes were constructed by adding 9 µl of transfection 
reagent to 38 µl of TCM-199 or G1 and incubated at room temperature for 5 minutes.   
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Table 9.  Experiment 10 transfection efficiencies. Two chemical reagents electroporated 
into bovine ova and embryos with laser compromised zona or zona intact blastocysts. 
 FuGENE GeneJammer 
Stage Zona 
No. 
Transfected 
% 
Transfected 
No. 
Transfected 
% 
Transfected 
Ova Drilled 38 0 39 0 
Zygote Drilled 35 0 36 0 
2 Cell Drilled 32 0 33 0 
4-6 Cell Drilled 28 0 29 0 
8 Cell Drilled 30 0 30 0 
16 Cell Drilled 12 0 12 0 
Morula Drilled 26 0 26 0 
Blastocyst Drilled 24 100 30 67 
Blastocyst Intact 15 88 12 92 
 
Then 3 µl Cy3-siRNA was added and the solution was allowed to sit for 15 minutes at 
room temperature before addition to the ova/embryos in culture medium.  Once the 
transfection solution was added, the ova/embryos were co-cultured for 24 hours and 
evaluated for fluorescence indicating successful Cy3-siRNA transfection.  Results 
indicated that transfection at any stage was not achieved until blastocyst formation at 
which point those transfected in FuGENE or GeneJammer had 100 and 97% transfection 
efficiencies, respectively.  In these blastocysts it appeared that the inner cell mass (ICM) 
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remained unaffected; however, further research is required to verify this observation.  
Following these results, zona intact blastocysts were co-cultured with transfection 
reagents as described above to evaluate the necessity of compromising the zona before 
transfection (Table 9).  Although transfection efficiencies were slightly diminished, 
blastocysts transfected with FuGENE or GeneJammer still achieved 88 and 92% 
transfection in embryos.  Chi Square analysis on combined blastocyst transfection data 
from both reagents indicates no difference in transfection efficiencies between zona 
drilled (98%) and zona intact (90%) treatments (P = 0.24).   
Considering all these data, it was concluded that current techniques for oocyte 
and embryo chemical transfection which have otherwise proven successful in the mouse, 
do not translate into the bovine.  Transfection of siRNA is inhibited in early stage bovine 
embryos until differentiation occurs at the blastocyst stage, likely due to changes in 
cellular architecture and polarization.  Either lipid based or cationic polymers are 
effective sirNA transfecting agents into blastocysts and although the laser drilling of the 
zona is not necessary, it can increase transfection efficiencies. 
 
 Electroporation 
  Electroporation based transfection applies unipolar electric field pulses to create 
transient aqueous pores through which the charged RNA/DNA molecules may pass 
(Schmotzer et al. 2003).  Parameters such as voltage, pulse length (µsec), the number of 
pulses, and how many series applied can be manipulated to determine the optimal 
settings for successful electroporation.  In the mouse, dsRNA targeted against both c-
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mos and GFP has been successfully delivered into oocytes and transgenic embryos 
(zygotes and 4-cell), respectively, using electroporation (Grabarek et al. 2002).  Spatial 
and temporal knock down of gene expression has also been accomplished in 
postimplantation mouse embryos removed from the uterus and electroporated in vitro 
(Mellitzer et al. 2002).  There are no known reports utilizing this technique in bovine 
embryos, therefore delivery of a GFP plasmid and Cy3-siRNA was attempted based on 
previous reports in the mouse. 
 
Experiment 11  
 Zonae from cumulus free bovine zygotes were laser drilled as previously 
described in 200 mmol L
-1
 sucrose and maintained in Holding medium until use.  Prior 
to electroporation, zygotes were washed three times through 20 mmol L
-1
 Hepes 
Buffered Saline (HBS) and transferred to HBS containing 5 µg ml
-1
 Fug-W plasmid.  
Embryos were then moved to a 3.2 mm square wire fusion chamber filled with 700 µl of 
HBS + Fug-W and electroporated with the parameters outlined in Table 10.  After 
treatment, embryos were washed twice through HBS and placed in G1/G2 sequential 
culture.  In addition, non-treated, laser only, and sucrose and HBS exposed embryos 
were cultured as controls.  None of the treatments successfully transfected the embryos 
as indicated by lack of green fluorescence among any group.  Except for embryos 
electroporated with 35 volts, all other treatments had noticeably reduced blastocyst 
development. 
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Table 10.  Experiment 11 parameters and blastocyst formation.  Embryo development 
rates following bovine zygote electroporation with 50 mg ml
-1
 of Fug-W plasmid. Blast, 
Blastocyst. 
Treatment Voltage Time (µs) # Pulses # Series # Zygotes % Blast 
Control ___ ___ ___ ___ 22 14 
Sucrose/HBS ___ ___ ___ ___ 30 30 
Laser Only ___ ___ ___ ___ 26 8 
Fug-W 20 100 2 3 26 8 
Fug 35 100 2 3 26 23 
Fug 50 100 2 3 24 8 
Fug 100 100 2 3 24 8 
Fug 200 100 2 3 28 4 
 
 
 
 
Experiment 12 
 Based on results in Experiment 11, the range of voltage used in Experiment 12 
was tailored to evaluate electroporation with 10, 30, or 60 volts and pulse time was 
decreased from 100 to 50 µsec for some of the trials (Table 11).  A 1.0 mm round wire 
chamber was used and 50 µmol L
-1
 of Cy3-siRNA was diluted into the HBS for 
electroporation.  After treatment, embryos were moved to sequential G1/G2 medium.  
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No cytoplasmic fluorescence was detectable in any of the embryos after treatment, 
however at 30 and 60 voltage for 100 µsec, a red glow was visible under fluorescent  
 
Table 11.  Experiment 12 parameters and blastocyst formation.  Embryo development 
rates following electroporation of bovine zygotes with 50 µmol L
-1
 of Cy3-siRNA. Blast, 
Blastocyst. 
 Treatment Voltage Time (µs) # Pulses # Series # Zygotes % Blast 
Control ___ ___ ___ ___ 23 30 
Cy3-siRNA 10 50 2 3 23 9 
Cy3-siRNA 30 50 2 3 14 0 
Cy3-siRNA 60 50 2 3 29 21 
Cy3-siRNA 10 100 2 3 19 21 
Cy3-siRNA 30 100 2 3 26 8 
Cy3-siRNA 60 100 2 3 35 6 
 
 
light in the perivitelline space indicating that the siRNA was moved from the 
surrounding medium to the embryos, but did not penetrate the cellular membrane.   After 
24 hours culture of these embryos Cy3 fluorescence was no longer detectable.  
Blastocyst development was varied across all treatments with a specific contributing 
factor unidentifiable. 
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Table 12.  Experiment 13 parameters and blastocyst formation.  Embryo development 
rates following electroporation of bovine zygotes injected subzonally with FuGENE 
complexed Cy3-siRNA FuGENE, injected with only transfection reagent; FuGENE:si, 
injected with compounded transfection reagent and Cy3-siRNA; Blast, Blastocyst. 
 Treatment Voltage Time (µs) # Pulses # Series # Zygotes % Blast 
Control ___ ___ ___ ___ 46 0 
FuGENE 10 50 3 3 31 0 
FuGENE 30 50 3 3 26 0 
FuGENE 60 50 3 3 27 0 
FuGENE:si 10 50 3 3 25 0 
FuGENE:si 30 50 3 3 29 0 
FuGENE:si 60 50 3 3 22 0 
 
Experiment 13 
 In a final effort to confine the siRNA near the embryo during electroporation, 
FuGENE was compounded with Cy3-siRNA in a 3:2 ratio and 100-150 pl were injected 
beneath the zona of cumulus free bovine zygotes.  Injected zygotes were electroporated 
in HBS in a 1.0 mm round wire chamber with parameters listed in Table 12 and then 
cultured in sequential G1/G2.  None of the treated groups exhibited red fluorescence nor 
did any group develop to the blastocyst stage.  
Given the time and multiple steps involved in the electroporation process coupled 
with the lack of success, no further experiments were attempted.  Electroporation was 
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deemed too injurious and as it was not effective to create transgenic bovine embryos, no 
further resources were allocated to this project. 
 
Streptolysin-O 
 Streptolysin-O (SLO) has been successfully used to deliver large molecules up to 
100 kDa in size through the membranes of cell cultures.  SLO can reversibly 
permeabilized cell membranes by forming pores in the lipid rafts allowing molecules 
through that would otherwise be too large for sodium pump channels.  Experimental 
parameters were based on previous work where SLO was utilized to permeabilized 
cellular membranes in fetal fibroblasts prior to SCNT (Sullivan et al. 2004). Bovine 
zygotes with either the zona intact, zona drilled, or zona removed were cultured with 1, 
10, 50, 100, and 500 IU of SLO (Sigma-Aldrich, St. Louis, MO) for 30, 60, 90, and 120 
minutes in a calcium and magnesium free TCM199 with Earle’s salts.  Propidium iodide 
was added to the culture as an indicator of pore formation as uptake would cause red 
fluorescence in the zygote cytoplasm.  After 30 minutes, lysis of zygotes had already 
begun in random treatment groups, and continued to increase as exposure time 
increased.  By 120 minutes, few red zygotes were visible in all treatments; however 
these zygotes looked deformed with cell membranes blebbing out.  After exposure to 
SLO, zygotes were washed through supplemented 199-Earle’s with 2 mmol L
-1
 calcium 
chloride to seal the pores and moved to sequential G1/G2 medium.  None of the zygotes 
exposed to the evaluated levels of SLO cleaved but rather had begun degrading.  The 
obvious failure of this experiment prevented any further exploration.   
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Conclusion 
 Direct injection continues to be the only method which is capable of successfully 
delivering siRNA into bovine zygotes while grouped embryo methods are thus far 
unsuccessful.  Injection of siRNA appears to alleviate distribution problems in the 
cytoplasm of zygotes as mosaic expression was reduced compared to those injected with 
plasmids.  None of the chemical methods evaluated effectively transfected zygotes or 
any other developmental stage for that matter until the blastocyst formation when 
trophectoderm cells were easily transfected.  The inner cell mass of these blastocysts did 
not appear to incorporate the Cy3-siRNA, although further validation is required.  
Neither electroporation nor pore formation was beneficial at the parameters tested.  Due 
to obvious deleterious effects early in the investigation, further variants of these 
experiments were not pursued.  For future experiments in bovine early embryo targeting 
specific genes, direct injection or trophectoderm transfection could be appropriate tools 
for expression knockdown with siRNAs. 
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CHAPTER III 
MATERIALS AND METHODS 
 
 Preliminary experiments in Chapter II investigating delivery of siRNA into 
bovine embryos suggested that microinjection into the cytoplasm of bovine zygotes or 
transfection of the trophectoderm in blastocysts could successfully deliver the Cy3-
siRNA.  Therefore, experiments were performed to determine if siRNAs targeting 
bovine E-cadherin could successfully knockdown gene expression after delivery by 
microinjection or transfection and evaluated for efficacy in sustaining gene knockdown 
in day 9 embryos. 
 
RNA isolation for gene sequencing 
 Small one inch strips of bovine kidney tissue collected from a slaughtered cow 
were immediately immersed in liquid nitrogen (LN2) after collection, wrapped in 
aluminum foil for storage, and maintained at -80ºC.  On dry ice, 50-100 mg of kidney 
tissue were shaved off in small flakes and collected into 1 ml of chilled RNA Stat-60 
(Tel-Test, Woodlands, Texas) in a 7 ml Dounce tissue grinder.  Flakes were ground until 
no tissue mass was detectable in a consistent homogenate, and then allowed to sit on ice 
for 5 minutes.  The homogenate was transferred into a 2 ml micro tube and 200 µl of 
chloroform was added.  The tube was shaken vigorously for 15 seconds to mix the 
chloroform and homogenate and then allowed to set undisturbed for 3 minutes at room 
temperature.  Samples were centrifuged for 15 minutes at 12,000 x g to separate into two 
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phases: the lower red phase containing protein topped with a white buffy coat of DNA, 
and the upper colorless aqueous phase containing RNA.   The aqueous phase was 
transferred to a clean 2 ml micro tube and 500 µl of isopropanol was added.  The 
samples were maintained at room temperature for 10 minutes and were then centrifuged 
at 12,000 x g for 10 minutes to form a white RNA pellet at the bottom of the tube.  After 
centrifugation, the supernatant was aspirated off leaving the RNA pellet behind which 
was washed with 1 ml of 75% ethanol, vortexed, and centrifuged again at 7,500 x g for 5 
minutes.  Supernatant was aspirated and the RNA pellet air dried for 5 minutes, after 
which 150 µl of nuclease free water was added to resuspend the pellet.  Isolated RNA 
samples were stored at -80ºC until use. 
 
mRNA purification for gene sequencing  
To extract the mRNA from the previously isolated total RNA, the Poly(A) Purist 
Kit from Ambion® (Austin, Texas) was used as directed.  Briefly, total RNA volume 
was brought up to 250 µl with nuclease free water to which 250 µl of 2x Binding 
Solution was added.  Samples were mixed and each was added to a column of oligo(dt) 
cellulose in a 2 ml micro tube, vortexed to mix, and incubated at 70ºC for 5 minutes.  
Columns were rocked at room temperature for 1 hour then centrifuged at 3,000 x g for 3 
minutes.  Supernatant was discarded and the cellulose column was washed with 500 µl 
of Wash Solution I followed by vortexing and centrifugation at 3,000 x g for 3 minutes.  
Filtrate was discarded and washed once more followed by 3 additional washes with 
Wash Solution II, discarding the filtrate after each wash.  The cellulose column was 
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transferred to a clean micro tube and 200 µl of warmed RNA Storage Solution was 
added, vortexed to mix, centrifuged at 5,000 x g for 2 minutes to extract the mRNA from 
the cellulose, and repeated once more.  To the filtrate 40 µl NH4Ac, 1 µl glycogen, and 
1.1 ml of 100% ethanol was added to precipitate the mRNA.  The samples were stored 
on dry ice for 30 minutes and centrifuged at 12,000 x g for 25 minutes to form a white 
mRNA pellet at the bottom of the tube.  Supernatant was discarded the pellet was 
washed with and 1 ml of 70% ethanol, vortexed, and centrifuged at 12,000 x g for 10 
minutes.  Again the supernatant was removed and the mRNA pellet was resuspended in 
50 µl of RNA Storage Solution and stored at -20ºC until use. 
 
Primer specifications for reverse transcription and gene sequencing 
 Primer sets for bovine E-cadherin (CHD1) were designed using the on-line 
software “Net Primer” and based on a human E-cadherin coding sequence listed in 
Genbank (Accession# NM_004360).  All primers were designed with a melting 
temperature (Tm) between 40-70ºC, around 50% GC content, hairpin formations <-4 
kcal/mol, primer diamerizations <-4 kcal/mol, and similar homology with <50 sequences 
in a BLAST report.  Primers were ordered on-line from Integrated DNA Technologies 
with standard desalting and rehydrated with nuclease free water to 100 µmol L
-1
.  Two 
gene specific primers were used for mRNA reverse transcription and 3 sets of 
overlapping primers were required for PCR amplification of the entire bovine E-cadherin 
coding sequence (Table 13). 
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Reverse transcription, PCR amplification and gel electrophoresis for gene sequencing 
 The Enhanced Avian Reverse Transcription kit (Sigma-Aldrich, St. Louis, MO) 
was used to amplify cDNA from the purified mRNA as directed.  Briefly, 5 µl of 
mRNA, 1 µl dNTP mix (500 µmol L
-1
 each dNTP), 1 µl of either “Af” or “Dr” primer 
(10 µmol L
-1
), and 3 µl of PCR grade water were combined in a 200 µl PCR micro tube 
and gently mixed.  Tubes were heated for 10 minutes at 70ºC to denature any secondary 
structures in the RNA, and then cooled to 4ºC to stop the reaction.   
 
Table 13.  E-cadherin primer sequences for reverse transcription (RT) and PCR 
amplification.  Rxn, Reaction; Prod. (nt), size of amplicon. 
Primer Sequence Rxn 
Prod. 
(nt) 
Anneal 
Temp. 
Af 5’ GCTTGCGGAAGTCAGTTCAG 3’ RT ____ 50ºC 
Dr 5’ CTGGCTCAAGTCAAAGTCCTG 3’ RT ____ 50ºC 
Red 5’ GCTTGCGGAAGTCAGTTCAG 3’ 
5’ ACCACACTCACAGTGACTGATGC 3’ 
PCR 1276 51ºC 
C1 5’ TGAACACCTACAATGCCGCCA 3’ 
5’ TGACCACCTCTCTCCTCCGA 3’ 
PCR 1334 58ºC 
Blue 5’ CGTGAGTCTCTGATTTTGAAGCC 3’ 
5’ AGGCGGCGAGGACGACTAG 3’ 
PCR 700 55ºC 
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Tubes were placed on ice and to each was added 2 µl 10x Buffer, 1 µl Enhanced AMV-
RT enzyme, 1 µl RNase inhibitor (20 units/µl), and 6 µl PCR grade water.  All samples 
were incubated at 50ºC for 50 minutes, cooled to 4ºC, and stored at -20ºC until use.  
Additionally, reactions omitting the primers were performed to detect any DNA 
contamination in the mRNA samples. 
 To PCR amplify the bovine E-cadherin coding sequence from cDNA, the 
Advantage® GC2 Polymerase Kit (Clontech, Mountainview, CA) was used.  For each 
reaction in a 200 µl micro tube, the following reagents were combined: 25 µl PCR grade 
water, 10 µl 5x GC2 PCR buffer, 10 µl GC Melt (5 mol L
 -1
), 1 µl 50x dNTP (10 mmol 
L
 -1
), 1 µl GC2 Polymerase, 1 µl cDNA, and 2 µl gene specific primer mix (10 µmol L
 -1
 
for each primer).  Each tube was placed in a thermocycler and reactions were performed 
under the following conditions: 94 ºC for 6 minutes (initial denature), 94 ºC for 30 
seconds (step 1 of cycle), specific primer annealing temperature (Table 13) for 30 
seconds (step 2 of cycle), 68 ºC for 1.5 minutes (step 3 of cycle), cycle repeated 35 
times, then heated to 68 ºC for 6 minutes (final extension) and held at 4 ºC upon 
completion.  Additional reactions omitting either the cDNA or the primers were 
performed to detect any contamination in the primer stocks or cDNA. 
 Amplified 50 µl samples were prepared for gel electrophoresis by adding 5 µl of 
Blue Juice™ loading buffer (Invitrogen, Carlsbad, CA) and mixing well.  A 10-well, 
1.2% w/v agarose gel made with 1X TAE buffer (Appendix B) and stained with 
ethidium bromide was prepared and allowed to solidify.  A total of 25 µl of each sample 
was loaded into the gel and 10 µl of Tri-Dye 2-log DNA ladder (New England Biolabs, 
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Ipswich, MA) was included to approximate DNA amplicon size.  Samples were 
electrophoresed at 60 mAmps for 30 minutes and then DNA migration was visualized 
under UV light in a light-tight box.   
DNA bands of appropriate size were excised from the gel and purified with a 
QIAEX II Gel Extraction Kit (QIAGEN, Valencia, CA) as directed.  The excised 
agarose was placed into a 1.5 ml tube and 1 ml of Buffer QX1 was added and heated for 
5 minutes at 50 ºC or until agarose completely melted.  To the agarose solution, 10 µl of 
QIAEX II was added, vortexed, and incubated at 50 ºC for 10 minutes.  The solution was 
centrifuged at 13,000 x g for 30 seconds and supernatant was aspirated leaving the DNA 
pellet behind.  The pellet was washed twice with 500 µl of Buffer PE followed by 
centrifugation for 30 seconds and allowed to air dry for 10 minutes.  Following the 
washes, collected DNA was resuspended in 20 µl of nuclease free water, incubated at 
room temperature for 5 minutes, centrifuged at 13,000 x g for 30 seconds, and the 
supernatant containing the DNA was collected into a fresh micro tube and sent to the 
Gene Technologies Laboratory at Texas A&M University for sequencing. 
 
E-cadherin siRNA sequences 
 Once the complete coding sequence for bovine E-cadherin was determined, it 
was submitted to Ambion (Austin, TX) for analysis.  Three siRNA sequences were 
produced (Table 14) with standard purification in 5 nmol L
 -1
.  Using nuclease free 
water, lyophilized samples were rehydrated to 100 µmol L
 -1
 and stored at -80ºC until 
validation in transfected MDBK cells with quantitative PCR and western blot analysis. 
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MDBK cell transfection 
 Mandin-Darby Bovine Kidney (MDBK) cells were cultured to ~70% confluence 
in 6-well tissue culture dishes in 2.0 ml of Glutamax (Gibco BRL, Rockville, MD) 
supplemented with 2.0 mmol L
 -1
 glutamine, 10 % v/v fetal bovine serum (FBS), and 1 
µl ml
 -1
 gentamicin (50 mg ml
 -1
) at 37 ºC in humidified 5% CO2 air.  To transfect the 
cells, 1 µl of either the negative control Cy3-siRNA (described in Chapter II), 
 
Table 14.  E-cadherin siRNA sequences designed by Ambion ® . 
Sequence Length Sense 
siEcad-12 21 bp 5’GGCAUCCUUGCUUUUCUGAtt 3’ 
5’ UCAGAAAAGCAAGGAUGCCtc 3’ 
siEcad-13 21 bp 5’ GCUAAGUUUUCUUGUCCAUtt 3’ 
5’ AUGGACAAGAAAACUUAGCtc 3’ 
siEcad-14 21 bp 5’ GGAGGUGGAGAAGAAGAUCtt 3’ 
5’ GAUCUUCUUCUCCACCUCCtt 3’ 
 
 
siEcad-12, siEcad-13, or siEcad-14 was combined with 6.3 µl of 2.0 mol L
 -1
 calcium 
chloride and 42.7 µl nuclease free water and mixed well.  To this solution, 50 µl of 2X 
Hepes Buffered Saline (HBS; Appendix C) was added drop wise while constantly 
flicking the tube to prevent precipitate from forming.  Once mixed the transfection 
solution was added to the cell cultures, mixed thoroughly into the culture medium, and 
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co-cultured for 20 hours.  After co-culture, cells were washed with calcium and 
magnesium free Dubelco’s Phosphate Buffered Saline (DPBS; Gibco BRL, Rockville, 
MD), given 2.0 ml of fresh supplemented Glutamax, and returned to the incubator for 48 
additional hours.  After 48 hours, cells were washed again with DPBS and collected for 
either RNA or protein isolation along with untreated cell samples for controls.  
 Transfection efficiency in each replicate was determined in two separately 
transfected cell cultures with the negative control Cy3-siRNA.  Prior to harvesting of 
cells for analysis, 8µl of 1 mg ml
-1
 Hoechst 33342 was added to the cells and incubated 
at 37ºC for 5 minutes.  Five digital images of each cell culture were taken at 20X with 
both UV and fluorescent light.  The total number of cells in each image was considered 
equivalent to the total number of fluorescent nuclei labeled with Hoechst.  The number 
of Cy3 fluorescent cells for each image was determined and divided by the total number 
of cells to obtain the proportion of cells which were successfully transfected per culture.  
Transfection efficiencies between the two samples were then averaged to obtain the 
presumed transfection efficiency for that replicate.  
 
Bovine zygote microinjection and blastocyst transfection 
 As described in Chapter II, bovine zygotes were produced in vitro by standard 
laboratory operating procedures and cumulus cells were removed by vortexing in 200 µl 
of warmed TL-Hepes (GIBCO, BRL, Rockville, MD) for 2 minutes.  After vortexing, 
zygotes were washed twice through warmed Holding medium consisting of TCM-199 
with Hank’s salts (GIBCO, BRL) supplemented with 10% v/v fetal bovine serum (FBS; 
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HyClone, Logan, UT) and 1% gentamicin (50 mg ml
-1
 solution; GIBCO, BRL) and 
either held for direct injection or cultured to the blastocyst stage in G1/G2 sequential 
medium (Vitrolife, Littleton, CO) supplemented with 8 mg ml
 -1
 Pentax BSA (Miles 
Laboratories, Elkhart, IN) and 1 µl ml
-1
 gentamicin at 38.5 ºC in 5% CO2, 5% O2, 90% 
N2 humidified air. 
 Microinjection procedures detailed in Chapter II were followed and presumptive 
zygotes were injected with 25 µmol L
 -1
 of either the negative Cy3-siRNA control or a 
Cy3 labeled siEcad in Holding medium under oil.  After injection, zygotes were washed 
once through G1 and cultured in G1/G2 sequential medium.  Day 7 blastocysts were 
transferred to fresh G2 and cultured until day 9 when non-treated and injected 
blastocysts were collected for analysis.  
 Chemical transfections were performed on day 7 in vitro produced blastocysts 
zona compromised by laser drilling in Holding medium supplemented with 200 µmol L
 -
1
 sucrose as previously described in Chapter II.  Transfection complexes were 
constructed by combining 9 µl of GeneJammer with 38 µl of G2 (no BSA or gentamicin) 
and incubating at room temperature for 5 minutes.  Either 3 µl of the negative Cy3-
siRNA control or 3 µl of the Cy3-siEcad were added to the transfection complex, mixed 
gently, and incubated at room temperature for 20 minutes.  After incubation, 50 µl of the 
transfection compound were added to the lasered blastocysts in 450 µl of G2 (no 
gentamicin) and incubated for 20 hours.  Blastocysts were then washed twice and 
transferred into fresh G2 medium and further cultured until collection on day 9 for 
analysis. 
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RNA isolation and cDNA synthesis for quantitative PCR (qPCR) 
 For qPCR analysis, the RNeasy Kit (QIAGEN, Valencia, CA) was used as 
directed with a few modifications.  To isolate RNA from MDBK cells, 350 µl of RLT 
RNA lysis buffer (no β-mercaptoethanol) was applied directly on DPBS washed cells 
and allowed to set for 1 minute.  The lysed cells and solution were pipetted into a 1.5 ml 
micro tube, passed through a 25 guage needle five times to further disrupt the cell 
membranes, then snap frozen in liquid nitrogen (LN2) and stored at -80ºC until 
purification.  To isolate RNA from bovine blastocysts, 10 blastocysts were washed 
through DPBS and transferred in as little fluid as possible into 75 µl of RLT (no β-
mercaptoethanol) in a 1.5 ml micro tube, vortexed for 2 minutes, then snap frozen in 
LN2, and stored at -80ºC. 
 Prior to RNA purification, samples were thawed on ice and vortexed for 2 
minutes.  To each sample of cells/blastocysts, 350/ 75 µl of 80% v/v ethanol was added, 
mixed by pipetting, and transferred into an RNeasy spin column.  Columns were 
centrifuged for 30 seconds at 10,000 x g and flow through was discarded.  The column 
was washed with 350 µl Buffer RW1 and centrifuged for 30 seconds at 10,000 x g, again 
discarding flow through.  In a clean 500 µl micro tube, 10 µl of DNase I and 70 µl of 
buffer RDD were mixed and then applied to the top of the filter membrane in the spin 
column and allowed to incubate at room temperature for 15 minutes.  After incubation, 
350 µl of buffer RW1 was added to the column which was then centrifuged for 30 
seconds at 10,000 x g.  The flow through was discarded, 500 µl of buffer RPE was added 
to the column and centrifuged for 30 seconds at 10,000 x g.  Flow through was again 
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discarded and 500 µl of 80% ethanol applied to the column and centrifuged for 2 
minutes at 10,000 x g.  The column was then removed from the micro tube and directly 
centrifuged at full speed with the column lid open for 5 minutes to allow the membrane 
to dry.  After centrifugation, the column was placed in a clean 1.5 ml mini tube and 
30/20 µl of nuclease free water was added directly on top of the membrane.  The column 
was centrifuged once more at full speed for 1 minute to collect the purified RNA and 
stored at -80ºC until use. 
   
Table 15.  E-cadherin and GAPDH primer and probe sequences for qPCR. BHQ, Black Hole Quencher. 
Gene 
Primer/ 
Probe 
Total 
Bases 
Amplicon 
Size Sequence 
E-cadherin Primers 20 
17 
76 bp 5’ GGTGTTTGATTATGAAGGAA 3’ 
5’ GGTCTTGGTCTGACTCT 3’ 
E-cadherin Probe 23 ____ 5’ /FAM/ TGGTTCCGAAGCTGCTA 
CTCTGA /BHQ/ 3’ 
GAPDH Primers 18 
19 
73 bp 5’ GGCATTCTAGGCTACACT 3’ 
5’ CGAAGGTAGAAGAGTGAGT 3’ 
GAPDH Probe 22 ____ 5’ /FAM/ AGGACCAGGTTGTCTC 
CTGCGA /BHQ/ 3’ 
   
 
To synthesize cDNA, the iScript cDNA Synthesis Kit (Biorad, Hercules, CA) 
was used as directed.  Briefly, 1 µg of MDBK RNA or the entire blastocyst RNA eluate 
were mixed with 4 µl 5x iScript Reaction Mix and Q.S. to 20 µl with nuclease free 
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water.  The samples were incubated for 5 minutes at 25ºC, 30 minutes at 42ºC, 5 minutes 
at 85ºC, and held at 4ºC until storage at -20ºC. 
 
Quantitative PCR  
 Primer sets for bovine E-cadherin and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) (Table 15) were ordered online through Integrated DNA 
Technologies and dual-labeled (fluorophore FAM and Black Hole Quencher) TaqMan® 
probes were ordered online from Biosearch Technologies (Novato, CA).  Lyophilized 
primers and probes were resuspended to 100 µmol L
 -1
 with DNase-free water, 
immediately aliquoted into single use doses to limit possible contamination, and stored 
at -20ºC until use. 
Synthesized cDNA from MDBK cells was subjected to SYBR® Green detection 
and samples from blastocysts were amplified with TaqMan® and dual labeled probes.  
Three experimental replicates were analyzed and all samples were performed in 
triplicate to detect E-cadherin and GAPDH in an ABI StepOne™ 48-well detection 
system.  Purified RNA from each sample was also directly amplified in triplicate to 
detect possible DNA contamination in the cDNA and reactions omitting cDNA were 
performed for each primer set to establish purity of primer and probe stocks.  In addition, 
a standard curve consisting of 5 samples increasing in concentration by a factor of 10 for 
each primer set was analyzed to validate appropriate primer performance.  
 For SYBR® Green detection, each reaction was performed in a 20 µl total 
volume and contained 10 µl Power SYBR® Green Master Mix (Applied Biosystems, 
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Foster City, CA), 2.5 µl each of sense and antisense primers (900 nmol L
 -1
), and 5 µl of 
cDNA diluted 1:10 in TE buffer and loaded into a 48-well plate covered with adhesive 
film.  Samples were then heated to 95ºC for 10 minutes and cycled 40 times at 95ºC for 
15 seconds followed by 60ºC for 1 minute.  A disassociation curve was also performed 
at the end of each qPCR experiment for all samples to detect non-specific PCR 
amplification by heating the samples at 95ºC for 15 seconds, decreasing the temperature 
to 60ºC for 1 minute, and then increasing the temperature in 0.3ºC increments back up to 
95ºC.   
For TaqMan® probe based detection, 20µl total volume reactions containing 10 
µl of TaqMan® Gene Expression Master Mix (Applied Biosystems, Foster City, CA), 
1.25 µl each of sense and antisense primers (900 nmol L
 -1
), 2.5 µl of probe (250 nmol L
 
-1
) and 5 µl of cDNA diluted 1:10 in TE buffer and were loaded into a 48-well plate 
covered with adhesive film.  Quantitative PCR reactions were heated to 50ºC for 2 
minutes, 95ºC for 10 minutes, and then cycled 40 times at 95ºC for 15 seconds followed 
by 60ºC for 1 minute.   
 
Protein isolation and western blot analysis 
 MDBK cells washed with DPBS were coated with 300 µl Protein Lysis Buffer 
(PLB; Appendix D), agitated until cells detached from the culture dish, then transferred 
into a 1.5 ml micro tube.  Groups of 20 bovine blastocysts from similar treatment groups 
were washed through DPBS and transferred in as little fluid as possible into 30 µl of 
PLB in a 1.5 ml micro tube and vortexed for 2 minutes.  All samples in PLB were 
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repeatedly snap frozen in LN2 then thawed at 37ºC five times and stored at -80ºC.  Prior 
to use, protein samples were thawed and centrifuged at 13,000 x g at 4ºC for 30 minutes.  
Supernatant was pipetted into a fresh micro tube and heated at 95ºC for 5 minutes to 
denature the proteins, then cooled to 4ºC.  For MDBK protein samples 20 µg of protein 
were combined with 5 µl of 4X Sample Buffer (Appendix E) and Q.S. to 20 µl.  
Blastocyst samples were prepared by combining 22 µl of isolated protein with 8 µl 4X 
Sample Buffer.   
 Buffered protein samples were electrophoresed at 100 volts for 1 hour in a 1 mm 
thick 5% polyacrylamide stacking gel layered on top of a 10% polyacrylamide resolving 
gel (Appendix F) in 1X Electrode Buffer (Appendix G).  For each gel, 20 µl of Precision 
Plus Protein Standards (Bio-Rad, Hercules, CA) was included for size approximation of 
migrated protein bands.  Gels were transferred to a PVDF membrane in Semi-Dry 
Anode Buffer (Bio-Rad, Hercules, CA) with a semi-dry transfer apparatus at 10 volts for 
20 minutes.  [All following washes and incubations were carried out in an orbital shaker 
or rocker].  PVDF membranes were blocked in 5% non-fat dry milk in tris buffered 
saline + 0.05% Tween (TBST) (Appendix H) for 1 hour at room temperature followed 
by overnight incubation in primary antibody targeted against E-cadherin (Table 16) 
diluted in 2% non-fat dry milk in TBST at 4ºC.  Membranes were washed 3 consecutive 
times for 10 minutes each wash in TBST and incubated for 1 hour at room temperature 
in the secondary antibody diluted in 2% non-fat dry milk in TBST.  The blots were then 
washed three more times in TBST for 10 minutes each wash and incubated 5 minutes at 
room temperature in 10 ml total of SuperSignal® West Pico Chemiluminescent 
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Substrate (Pierce, Rockford, IL) while protecting from light.  Membranes were placed 
inside a clear sheet protector and imaged in an AlphaInnotech light tight system.  
Densities of acquired chemiluminescent bands were measured with AlphaInnotech 
Alpha Ease Software v. 4.0.  After imaging, blots were washed twice in TBST for 10 
minutes at room temperature, and then incubated at 60ºC in 20 ml of Stripping Buffer 
(Appendix I) to remove antibodies.  Blots were re-blocked and incubated with antibodies 
(Table 16) for the selected endogenous control genes (either GAPDH or β-actin) and 
then analyzed as described above.  Controls for MDBK cells omitted incubation in the 
primary antibody to asses any non-specific binding of the secondary antibody.      
 
Immunocytochemistry with bovine blastocysts 
 Prior to fixing, blastocysts were washed once through DPBS then held for 3 
minutes in 500 µl of warmed 0.5% Pronase E in TCM199 with Hank’s salts + 10% FBS 
(199-Hank’s) to remove the zona.  Zona-free embryos were then washed three times 
through 500 µl of 199-Hank’s and twice more through DPBS.  Successive cold methanol 
(MeOH) dilutions (-20ºC) in DPBS were used to fix the embryos by first holding them 
in 1:1 MeOH:DPBS for 2 minutes, then in 2:1 MeOH:DPBS for an additional 2 minutes.  
Blastocysts were then washed for 5 minutes in DPBS + 0 .01% Tween (PBST) on an 
orbital rocker before overnight incubation at 4ºC in Blocking Buffer (Appendix J).  
Embryos were incubated in primary E-cadherin antibody (Table 17) diluted 1:50 in 
Blocking Buffer at a density of 1 embryo/10 µl of buffer for 4 hours at room temp, 
followed by 6 washes for 20 minutes each through fresh Blocking Buffer on an orbital 
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shaker.  The secondary antibody (Table 17) was diluted 1:100 in PBST and embryos 
were incubated overnight at 4 ºC in a similar density as the primary antibody.   
 
Table 16.  Antibodies used for western blot analysis. 
Gene Antibody Source Application – Dilution 
E-cadherin 1º Anti-Rabbit 
Monoclonal 
Millipore #07-697 
(Burlington, MA) 
MDBK Cells – 1:5,000 
Blastocysts – 1:5,000 
GAPDH 1º Anti-Rabbit 
Polyclonal 
Affinity Bioreagent 
#PA3-16782 
(Golden, CO) 
MDBK Cells – 1:5,000 
E-cadherin 
GAPDH 
2º Goat  
Anti-Rabbit 
IgG H&L 
Invitrogen 
#G-21234 
(Carlsbad, CA) 
MDBK Cells – 1:10,000 
 
β-actin 1º Anti-Mouse 
Monoclonal 
AC-15 
Abcam 
#ab6279 
(Cambridge, MA) 
Blastocysts – 1:5,000 
β-actin 2º Goat  
Anti-Mouse 
IgG H&L 
Invitrogen 
#M30007 
(Carlsbad,CA) 
Blastocysts – 1:10,000 
 
Upon completion of antibody labeling, embryos were washed twice through PBST and 
mounted on a glass microscope slide in 10 µl of Mounting Medium (Appendix K).  A 
64 
glass cover slip was very gently layered on top of the blastocysts and sealed with clear 
nail polish.  Scanning confocal images were taken by Dr. Roula Mouneimne at the Texas 
A&M College of Veterinary Medicine Image Analysis Lab to detect fluorescence 
intensity of labeled E-cadherin in each embryo.  A Meridian Ultima Confocal 
Microscope was used for image capture at 20x by excitation of the fluorophore with an 
argon laser at 488 nm and emission at 515-530 nm in a total of 35 z-series sectionals, 1 
µm apart.  Confocal images of embryo area and intensity were measured with Adobe 
Photoshop® to determine an average intensity of E-cadherin expression for each embryo 
evaluated.    
 
Table 17.  Antibodies used for immunocytochemistry. 
Gene Antibody Source Application - Dilution 
E-cadherin 1º Mouse  
Monoclonal 
IgG2a 
BD Biosciences 
#610F1 
(San Jose, CA) 
Blastocysts – 1:50 
E-cadherin 2º Goat  
Anti-Mouse 
Alexa Fluor 488 
Imgenex 
#A11001 
(San Diego, CA) 
Blastocysts – 1:100 
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Statistical analysis 
 The Ct values from similar replicates collected during qPCR were averaged and 
the ∆∆Ct method (Hettinger et al. 2001) was used to determine relative quantitation of 
E-cadherin gene expression compared to the endogenous control gene GAPDH.   
A Student’s T-test was performed with Microsoft Excel software to determine 
significant differences in E-cadherin gene expression with P < 0.05.  Density 
measurements were taken of western blot bands within a set pixel area to obtain an 
average light density measurement for E-cadherin and GAPDH.  Relative density for 
each sample was determined and subjected to ANOVA analysis using JMP 5.1 statistical 
software to detect significance with P < 0.05 and a Dunnett’s test with P < 0.05 
significance was used for comparisons of each treatment to the control when ANOVA 
indicated differences within the data.  Fluorescence intensity of E-cadherin was averaged 
among all ICC processed embryos in similar treatment groups and compared with 
ANOVA and Student’s T-tests with significance in expression differences considered 
when P < 0.05.    
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CHAPTER IV 
RESULTS 
 
Bovine E-cadherin coding sequence 
Amplicon sequences from three overlapping primer sets were compiled to 
establish the coding sequence (linear mRNA) for bovine E-cadherin.  The resulting gene 
was submitted to GenBank and assigned the accession number AY508164 on January 
17
th
, 2004.  The coding portion of the gene contains 2649 base pairs which translate into 
an 882 amino acid protein and the nucleotide sequence is given below in Figure 10. 
 
 
5’ATGGGCCCTTGGAGCCGCAGCCTCTCTGCGCTCTGCTGCTGCTGCAGGTGT
AATCCGTGGCTCTGCCGGGAGCCGGAGCCCTGCATTCCTGGCTTTGGTGCTG
AGAGTTACACGTTCACCGTGCCCCGGCGGAACTTGGAGAGAGGGCGAGTCC
TAGGCAGAGTGAGTTTTGAAGGATGTGCTGGCCTACCAAGGACAGTCTATGT
TTCTGATGACACCCGATTCAAAGTGCACACAGATGGCGTGCTTACAGTCAGA
CGACCTGTACACCTTCATCGTCCAGAGCTAAGTTTTCTTGTCCATGCCTGGGA
CTCCACCCACAGGAAGCTCTCCACCAAAGTGACACTGGAGGTATCAGCGCA
CCACCACCACCACCACAGTCATCATGACTCTCCCTCTGGAACCCAGACAGAA
GTGCTCACATTTCCTGGCCCCCACCATGGTCTCAGGAGACAGAAGAGAGACT
GGGTTATTCCTCCTATCAGCTGCCCAGAAAATGAGAAAGGCCCATTTCCTAA 
Fig. 10.  Bovine E-cadherin coding sequence. 
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GTCGCTGGTCCAGATCAAATCTAACAAGGAGAAAGAAACCCAAGTTTTCTAC
AGCATCACTGGCCAACGAGCTGATACACCCCCTGTCGGTGTTTTTATTATTG
AAAGAGAAACAGGATGGTTAAAAGTGACACAGCCTCTGGATAGAGAACAGA
TTGCCAAGTACATTCTCTTCTCTCATGCCGTGTCTTCAAATGGACAAGCCATT
GAAGAGCCTATGGAGATTGTGATCACCGTGACCGACCAGAATGACAACAAG
CCCCAGTTCACCCAGGAGGTCTTCAAGGCGTCTGCCCTGGAAGGCGCTCTTC
CAGGAACCTCTGTGATGCAGGTCACGGCCACAGATATAGATGACGAGGTGA
ACACCTACACCGCTGCCATCGGTTACACAATCCCAGCCCAAGATCCCATGCT
GCCGCACAACAAAATGTTCACCATCAACAAGGAAACAGGCGTCATCAGTGT
GCTCACCACCGGGCTGGACCGTGAGAGTTTTCCCACATACACCCTGATGGTC
CAAGCAGCAGACCTTAACGGCGAAGGCTTGAGCACAACTGCAACGGCCGTG
ATCACAGTCTTGGACACCAATGATAATGCTCCCAGATTCAACCCAACCACGT
ACGTGGGGTCGGTGCCTGAGAACGAGGCTAATGTGGCCATCACCACACTCA
CAGTGACTGATGCCGACGACCCCAACACCCCGGCATGGGAGGCTGTTTACAC
AGTATTAAATGATAACGAGAAGCAATTTATCGTCGTCACAGACCCAGTCACC
AATGAAGGCACTCTGAAAACAGCTAAGGGCTTGGATTTTGAGGCCAAGCAG
CAGTACATCCTGTACGTGGCAGTGACAAATGTGGCCCCCTTTGAAGTCACTC
TCCCCACTTCCACAGCCACCGTCACTGTGGATGTGATAGATGTGAATGAAGC
CCCCATCTTTGTGCCTCCTCAAAAGAGAGTGGAAGTGCCCGAGGACTTTGGC
GTGGGCCTGGAGATCACATCCTATACTGCCCGGGAGCCAGACACATTTATGG
AACAGAAGATCACGTATCGGATTTGGAGGGACACTGCCAACTGGCTGGAGA 
Fig. 10. Continued. 
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TTAATCCAGAAACGGGTGCCATTTCCACTCGGGCTGAGTTGGACAGAGAGG
ATGTCGATCATGTGAAGAACAGCACGTACACGGCCCTCATTATAGCCACTGA
CAATGGTTCTCCACCTGCCACTGGGACAGGCACCCTGCTCTTGTTCCTCGATG
ATGTGAATGACAATGGCCCCGTACCAGAACCCCGGACCATGGACTTCTGCCA
GAGGAATCCTGAGCCTCATATCATCAACATCAATGATCCTGATCTCCCTCCG
AACACCTCCCCCTTTACAGCAGAACTGACACATGGGGCGAGTGTCAATTGGA
CCATTGAGTACAATGACCAAGAACGTGAGTCTCTGATTTTGAAGCCAAAGAA
AACCTTAGAGCTGGGTGACCACAAAATCAATCTCAAGCTCATAGACAACCA
GAACAAAGACCAGGTGACCACACTTGATGTGCACGTGTGTGACTGTGATGG
GATCGTCAGCAACTGCAGGAAGGCACGGCCTGCTGAAGCAGGATTGCAAGT
TCCCGCCATCCTGGGGATCCTTGGAGGCATCCTTGCTTTTCTGATCCTTATTT
TGCTGCTTCTGCTACTTGTTCGGAGGAGAAGGGTGGTCAAAGAGCCCTTACT
GCCCCCAGAAGATGACACCCGGGACAATGTGTATTACTATGATGAAGAAGG
AGGTGGAGAAGAAGATCAGGACTTTGACTTGAGCCAGTTACATAGGGGCCT
GGATGCTCGGCCTGAAGTGACTCGCAATGACGTGGCACCAACCCTCATGAGT
GTGCCCCAGTACCGACCCCGCCCTGCCAATCCTGATGAAATTGGAAACTTTA
TTGATGAAAACCTGAAGGCAGCTGATAGTGACCCCACTGCCCCACCCTATGA
CTCTCTGCTGGTGTTTGATTATGAAGGAAGTGGTTCCGAAGCTGCTACTCTG
AGCTCCCTGAACTCCTCAGAGTCAGACCAAGACCAGGACTATGACTACCTGA
ATGAATGGGGCAATCGCTTCAAGAAGCTGGCGGACATGTATGGAGGCGGCG
AGGACGACTAG 3’ 
Fig. 10.  Coninued. 
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E-cadherin specific siRNA validation 
 The three siRNA sequences developed by Ambion® (Table 14) based on the 
above E-cadherin sequence and a null Cy3-siRNA were transfected into MDBK cells to 
identify which custom designed siRNA induced the greatest knockdown of mRNA and 
protein expression as assessed by qPCR and western blot analysis.  Transfections were 
performed in three replicates for each method of assessment and transfection efficiencies 
based on duplicated Cy3 fluorescent cells in each replicate ranged from 92.5-95.0%.  
Expression levels were quantified individually in each replicate, and then averaged by 
treatment across all experiments for comparison and statistical analysis. 
 SYBR® Green based qPCR analysis measured the Ct value for E-cadherin and 
GAPH in each replicate and the Ct mean and ∆Ct mean were calculated and reported in 
Appendix L.  All ∆Ct mean values in similar treatments from all replicates were 
combined into ∆∆Ct calculations to obtain the fold difference between treatments which 
was then log10 transformed to ascertain relative changes in gene expression and 
standard error of the mean (± S.E.M.).  A Student’s T-test was performed to determine 
significance (P < 0.05) between each treatment and the non-treated Control and Cy3-
siRNA null.  There was no difference in relative E-cadherin gene expression in any of 
the treatments compared to the Control (1.02 ± 0.26) (Figure 11).  However, siEcad-13 
and siEcad-14 (0.62 ± 0.37 and 0.84 ± 0.22, respectively) had significantly diminished 
expression compared to the null, Cy3-siRNA (1.19 ± 0.25), which was not different from 
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siEcad-12 (1.21 ± 0.45).  Disassociation curves for each replicate confirmed appropriate
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Fig. 11.  Expression levels of E-cadherin mRNA.  MDBK cells were transfected with a 
null siRNA (Cy3-siRNA) or with sequence specific siRNAs.  Bars indicate standard 
error of the mean (± S.E.M.).  Differences in letters indicate significance at P < 0.05. 
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SYBR® Green signal amplification and negative controls indicated no contamination in 
the cDNA or primers.  
Density measurements within a fixed pixel area were obtained for E-cadherin and 
GAPDH in MDBK transfected cells from western blot image analysis (Figure12).  Two 
protein bands were consistently detected with E-cadherin antibody labeling between 
100-150 kDa.  The larger protein did not appear to be affected by E-cadherin siRNA 
interaction, while the smaller appeared around 106 kDa, the presumed size for E-
cadherin, and responded appropriately to treatment with siRNAs.  GAPDH proteins were 
detected at the expected size, approximately 38 kDa, in every replicate.  Density ratios 
and relative protein expression levels were calculated and reported in Appendix M and 
ANOVA analysis indicated significant differences in E-cadherin expression between 
treatments (P < 0.0001).  A Dunnett’s test further indicated all three E-cadherin specific 
siRNAs significantly decreased protein expression by 69% (siEcad-12), 73% (siEcad-
13), and 72% (siEcad-14) when compared to the non-treated Control (Figure 13), and by 
49, 53, and 52%, respectively, when compared to the null Cy3-siRNA. 
 Based on these data, siRNA-13 was identified as an appropriate sequence for 
experiments in bovine embryos.  A new sequence was produced by Ambion® with a 
Cy3 label on the 5’ end and is further referred to as Cy3-siEcad.  
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Fig. 12.  Western blot analysis with transfected MDBK cells.  Three replicates 
transfected with null Cy3-siRNA (Cy3-1, Cy3-2) or E-cadherin specific siRNA (si-12, 
si-13, si-14).  Expected E-cadherin proteins are approximately 106 kDa and GAPDH 
about 38 kDa.  
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Fig. 13.  Relative E-cadherin protein expression in transfected MDBK cells. Null siRNA 
(Cy3-siRNA) or sequence specific siRNAs are compared to the non-treated Control.  
Bars indicate standard error of the mean ( ± S.E.M.) and different letters indicate a 
significant difference with P < 0.0001 
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Analysis of E-cadherin expression in Cy3-siEcad treated bovine embryos 
 Day 1 bovine zygotes were injected and day 7 blastocysts were transfected with 
null Cy3-siRNA or E-cadherin specific Cy3-siEcad siRNAs. Groups of 10 similarly 
treated blastocysts were collected on day 9 and analyzed for E-cadherin and GAPDH 
gene expression utilizing TaqMan® based qPCR.  The Ct values were measured and the 
∆Ct for each replicate was determined, averaged by treatment (Appendix N), and then 
combined into a ∆∆Ct analysis for all replicates to obtain relative expression levels 
(Figure 14).  Statistical analysis was performed with a Student’s T-test and significance 
was considered when P < 0.05.  Compared to the Control (2.83 ± 0.01), there was no 
difference in E-cadherin expression in either of the null Cy3-siRNA treatments (2.99 ± 
0.09, injected and 2.87 ± 0.11, transfected), however Cy3-siEcad injected embryos had 
significantly more mRNA expression (3.01 ± 0.01; P < 0.005).  There was significantly 
less E-cadherin detected in Cy3-siEcad transfected embryos (2.55 ± 0.09) compared to 
the non-treated and null Cy3-siRNA transfection control embryos (P < 0.05).   
 Groups of 20 blastocysts were collected from each treatment and relative E-
cadherin protein expression was compared to β-actin.  Three replicates were performed, 
however, only one appropriately labeled both proteins and is therefore demonstrative of 
proof-of-concept only and not subject to statistical analysis.  Graphical representation in 
Figure 15 illustrates that there was very little variation in relative protein expression 
between treatments with expression ratios ranging from 0.99 – 1.09.  
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Fig. 14.  Relative expression of E-cadherin mRNA in day 9 blastocysts.  Embryos were 
either injected at the zygote stage (Null-Inj and Ecad-Inj) or transfected at day 7 (Null-
Trfx and Ecad-Trfx).  Different letters indicate significant changes in expression with P 
< 0.05.  Error bars represent the standard error of the mean (± S.E.M.) 
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Fig. 15.  Western blot display and relative expression of E-cadherin in day 9 blastocysts.  
Bovine embryos were either injected (Inj) or transfected (Trfx) with Cy3-siRNA (null) 
or Cy3-siEcad (Ecad). 
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To further evaluate protein expression, a more sensitive method was used to 
detect changes in E-cadherin intensity in individual embryos.  Four to five blastocysts 
from each treatment were subjected to immunocytochemistry and E-cadherin antibody 
fluorescence intensity was measured with scanning confocal microscopy.  Intensity 
measurements were averaged within each treatment and analyzed with ANOVA and 
Student’s T-test with P < 0.05 (Figure 16).  Compared to the Control, there was no 
difference in intensity among any of the treated groups.  Although there was a tendency 
in Cy3-siEcad injected embryos to express less E-cadherin than the Cy3-siRNA null, the 
overall intensities of these treatments was not significantly different.  Furthermore, E-
cadherin expression did not differ between the blastocysts transfected with the null and 
E-cadherin siRNAs.  The only statistical difference in these data was between the two 
Cy3-siEcad treatments where injected embryos had decreased protein expression 
compared to those which were transfected (P < 0.05). 
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Fig.16. Fluorescence intensity of E-cadherin in ICC labeled day 9 blastocysts.  Bovine 
embryos were either injected or transfected with null or E-cadherin specific siRNAs.  
Error bars indicate the standard error of the mean (± S.E.M.) with P < 0.05. 
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CHAPTER V 
DISCUSSION AND CONCLUSION 
 
E-cadherin forms the main component of the adherent junctions between 
trophectoderm cells and has been demonstrated to be absolutely required for cellular 
differentiation and blastocoel formation in bovine embryos (Barcroft et al. 1998).   
Therefore, E-cadherin was selected as the target gene to compare two methods for 
delivery of siRNAs to knock down gene expression in hatched (day 9) bovine embryos 
for several reasons.  First, there is an obvious knockout phenotype which is easily 
recognizable upon visualization.  Second, bovine E-cadherin has been characterized in 
early embryo trophectoderm (Barcroft et al. 1998) and antibodies have been developed 
and validated for appropriate detection. Third, previous experiments in both the mouse 
and cow have demonstrated the ability to effectively decrease E-cadherin gene 
expression up to day 7 (Nganvongpanit et al. 2006a; Wianny and Zernicka-Goetz 2000) 
in embryos by microinjecting dsRNA.  
Since publication of the complete coding sequence for bovine E-cadherin in 
GenBank (Figure 10), there has been one additional entry describing the complete 
mRNA sequence (Accession# BC147914) obtained from bovine fetal fibroblast RNA.  
A ClustalW alignment between the two sequences indicates 99.02% homology with 
2623/2649 base pairs aligning in a similar arrangement.  In addition, Nganvongpanit et 
al. 2006, designed long dsRNA based on the gene sequence detailed here and 
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demonstrated successful targeting of bovine E-cadherin in early stage embryos.  Given 
these reports, it is with confidence that the coding sequence presented within (Figure 10) 
is at least 99% accurate.  Furthermore, properly designed siRNAs targeting bovine E-
cadherin based on this sequence has a 99% chance to be completely homologous to its 
target and can be expected to induce post transcriptional gene silencing.  
Ambion® guarantees that two out of the three gene specific siRNA sequences 
they design will induce at least 80% protein expression knock down in most mammalian 
cell lines.  All three of the siRNA sequences evaluated in this report against E-cadherin 
in MDBK cells decreased protein expression by approximately 70% compared to the 
control and by 50% when compared to the null transfected cells.  However mRNA 
expression profiles were somewhat different after MDBK cell transfection.  Both 
siEcad(13) and siEcad(14) significantly reduced detectable E-cadherin mRNA compared 
to the null Cy3-siRNA control, but siEcad(12) treated cells were not different from 
either the control or null treated cell populations.  This can be attributed to one of the 
qPCR replicates for siEcad(12) which produced a much lower ∆Ct Mean value, most 
likely due to a pipetting error when setting up the reaction, skewing the relative quantity 
value slightly higher.  Although removal of this replicate from the ∆∆Ct calculations 
would have lowered the overall relative quantity of siEcad(12), this difference compared 
to the Cy3siRNA control was calculated not to have been significant and therefore the 
replicate values remained in the final expression profile report.  Based on these data, a 
Cy3 labeled siEcad(13) (Cy3-siEcad) was chosen to attempt knock down of E-cadherin 
in zygote and blastocyst stage bovine embryos.   
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The expected outcome after introduction of siEcad(13) into early bovine embryos 
was that both protein and mRNA expression would be noticeably altered in the injected 
zygotes and transfected blastocysts, similar to what was observed in the MDBK cells.   
However, by day 9 of embryonic development, there was no observable difference in E-
cadherin mRNA expression in Cy3-siEcad injected zygotes as opposed to those injected 
with the null Cy3-siRNA (Figure 14).  There was however a significant increase in 
expression when compared to the non-treated control, but this probably is due more to a 
difference in the quality of embryos rather than interactions of the siRNA.  Zygotes 
which are capable of continued development after microinjection tend to derive from 
better quality oocytes creating a population of embryos that are predominantly healthier 
than a control population which may include a mixed assortment, some of the embryos 
representing inferior quality detectable in qPCR analysis.  
Conversely, day 7 blastocysts transfected with Cy3-siEcad did express a 
significant decrease in mRNA on day 9 compared to either control (Figure 14), a result 
which was expected.  Cy3 fluorescence provided visual confirmation of successful 
transfection into the trophectoderm and was still slightly visible at the time of blastocyst 
collection for analysis, indicating the potential for sustained siRNA activity.  Therefore 
it was reasonable to expect to see a significant decrease in E-cadherin mRNA after 48 
hours of siRNA interaction, similar to what was observed in the MDBK cells.  It is 
interesting that significantly less E-cadherin mRNA was detected in blastocysts 
transfected with siEcad(13) than in zygotes injected with siEcad(13).  This would seem 
to demonstrate that the continuance of injected siRNAs at 25 µmol L
-1
 into zygotes does 
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not persist more than 7 days, suggesting targeted suppression of genes associated with 
hatching and elongation is unlikely to succeed with this technique.  Not only did these 
data indicate E-cadherin mRNA was successfully targeted, but also siEcad(13) was 
100% homologous to the target inducing mRNA degradation presumably through the 
siRNA processing pathway detailed in Figure 3.  Additionally, this further validates the 
accuracy of the E-cadherin coding sequence presented in Chapter IV (Figure 10). To 
date, this is the first report describing successful post transcriptional gene silencing in 
bovine blastocyst trophectoderm cells using transfected siRNAs. 
Given the results from mRNA analysis the complete lack of protein expression 
knockdown in similarly treated embryos (Figure 15) was surprising.  Western blot 
analysis protein quantification detected virtually no difference in E-cadherin expression 
levels among any of the treatments in the one replicate which was available for analysis.  
However, in the remaining two replicates in which β-actin was not detectable, making 
quantification data unobtainable, E-cadherin density measurements were consistently 
similar to what was observed in the first replicate.  This would suggest that changes to 
protein levels in the blastocysts truly were not detectable with western blot.  
Since western blots do not always provide sensitive detection of minute changes in 
protein intensity; ICC was utilized to measure E-cadherin protein expression in 
individually immuno-labeled blastocysts.  Although there was no statistical difference in 
the protein levels between the Control and injected embryo treatments (Figure 16), there 
was a tendency for Cy3-siEcad injected zygotes to exhibit less fluorescent emissions 
than the Control or null injected embryos.  Neither the null nor siEcad(13) transfected 
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blastocysts differed from the Control or each other, however, unlike the mRNA analysis, 
there was a significant amount more of E-cadherin protein detected in the transfected 
embryos than in the Cy3-siEcad injected zygotes.  It is strange that mRNA but not 
protein levels would be affected by blastocyst transfection.  The half-life of E-cadherin 
in confluent epithelial cells is 5-10 hours (Gumbiner 2000) and therefore it is expected 
that protein levels in the embryos would diminish within 24 hours after siRNA  
transfection.  However, the most likely reason for no detectable change in E-cadherin 
protein expression is probably due to a flawed method of blastocyst collection.  In the 
Cy3-siEcad transfected blastocysts, trophectoderm cells were already beginning to 
disassociate blastocysts on day 9.  These unincorporated cells however were not 
collected along with the blastocyst for analysis so that E-cadherin and GAPDH levels 
were only measured in the healthy or unaffected cells which remained in the 
trophectoderm, thus protein levels appeared to be unaltered.   
These E-cadherin protein expression data would also reaffirm that injected 
siRNAs are depleted in developing embryos well before day 9 when E-cadherin 
expression levels are evaluated.  E-cadherin transcript levels apparently are able to re-
establish normal quantities and embryo development continues in a belated time line, as 
represented in Figure 17, which depicts the delayed blastocoel development in Cy3-
siEcad injected zygotes.  On day 7, both the Control and null Cy3-siRNA blastocysts 
had an obvious blastocoel formed and were beginning to expand.  The Cy3-siEcad 
injected embryos did not have a blastocoel and appeared similar to a large morula before 
compaction.  By day 8, blastocysts from both control groups had begun to hatch whereas  
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Fig. 17.  Embryo development in injected zygotes.  Blastocyst formation in day 7, 8, and 
9 bovine embryos from non-treated Control, Cy3-siRNA injected, or Cy3-Ecad injected 
zygotes.  Both Control and Cy3-siRNA embryos display normal progression from 
blastocoel formation on day 7 (A and B) to hatching on day 8 (D and E), and fully 
hatched blastocysts by day 9 (G and H).  Cy3-siEcad injected zygotes have delayed 
development with blastocoel formation beginning on day 8 (F) and hatching initiating on 
day 9 (I).  White scale bars = 50 µm at 20X, blue scale bar (E) = 100 µm at 10X, and 
green scale bar (C) = 25 µm at 40X. 
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the Cy3-siEcad embryos just begun blastocoel formation and did not initiate hatching 
until day 9 by which point the control embryos were completely hatched.   
 Although protein expression levels appeared unaffected in embryos by the 
siRNAs, transfected blastocysts which were allowed to continue in culture for an 
additional 24 hours to day 10 underwent complete trophectoderm disintegration, 
presumably as a result of siRNA induced PTGS (Figure 18).  On the day of data 
collection for this project (day 9), Cy3-siEcad transfected blastocysts already had begun 
to exhibit signs of trophectoderm cell adhesion loss whereas the null control appeared 
normal, comparable to an in vitro derived embryo.  By day 10 of culture, while the Cy3-
siRNA transfected blastocysts continued to expand, the trophectoderm of E-cadherin 
targeted blastocysts had completely disassociated leaving behind multiple inner cell 
mass structures.  This would indicate that the siRNAs were actually functioning as 
expected, but protein degradation in embryos appears to be delayed compared to 
epithelial cell cultures. 
Undoubtedly, these presented data demonstrate efforts towards altering gene 
expression in hatching and elongating bovine embryos with siRNAs should be attempted 
by transfection at the blastocyst stage once cell differentiation has occurred.  Although it 
is possible that higher concentrations of injected siRNAs could sustain gene silencing to 
the blastocyst stage, early studies reported in Chapter II indicate decreased development 
with injected concentrations of 50 µmol L
-1
 or greater.  Unfortunately, at this time, 
current techniques for blastocyst transfection do not appear to affect the inner cell mass 
(ICM).  The mechanisms for chemical transfection described in Chapter II involve 
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endocytotic and membrane fusion pathways which conclude in the cytoplasm and do not 
employ exocytosis.  Therefore it is not possible for the chemical transfection reagents to 
pass completely through the trophectoderm and then attempt to further transfect cells in 
the ICM (Rossant 2007).  However, this limited access to the ICM associated with 
blastocyst transfection could be beneficial in altering trophectoderm gene function 
without contaminating the embryo with transgenes.  Gene expression anomalies could 
potentially be rescued and functional genomics during elongation could be assessed with 
relatively simple treatments to the embryos before transfer.   
Future directions for this project may include developing treatments for bovine 
blastocysts with siRNAs targeted against apoptotic genes, such as bax, before embryo 
transfer to reduce the incidence of apoptosis and increase implantation rates in a 
commercial production setting (Yang and Rajamahendran 2002).  siRNA transfection 
may also be useful in treating cloned embryos before transfer to reduce highly aberrant 
gene regulation of DNA methyltransferase 1 which can lead to improper epigenetic 
modifications, failed development and implantation (Giraldo et al. 2008).  Treatment of 
blastocysts with siRNAs targeting E-cadherin could also server as an alternative to 
immunosurgery for isolating ICM cells for stem cell isolation.  Figure 18(D) depicts the 
complete removal of trophectoderm cells surrounding the inner cell mass after 
transfection with Cy3-siEcad.  This resulting morphology would alleviate the need for 
complicated embryo manipulation associated with immunosurgery, although further 
modifications would warrant investigation to reduce structural damage to the ICM 
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Fig. 18.  Trophoblast morphology in transfected blastocysts.  Bovine embryos 
transfected on day 7 with the null Cy3-siRNA or gene specific Cy3-siEcad and cultured 
to day 10.  Null treated blastocysts continue to expand (A and B)while the 
trophectoderm cells in E-cadherin targeted blastocysts begin to disassociate on day 9 (B) 
until the trophectoderm  disintegrates leaving only the inner cell mass behind (D).   
 
    GeneJammer has been used to optimize adenovirus gene delivery into porcine 
mesenchymal stem cells and it is possible that similar success could result with lentivirus 
mediated gene transfer into the trophectoderm of bovine blastocysts (Bosch et al. 2006).  
A B 
C D 
 Day 9 
Day 10 
Cy3-siRNA Cy3-siEcad 
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Such stable gene knockdown would make genes involved in implantation and pregnancy 
maintenance more accessible for study or regulation.  Alternatively, lentiviral delivered 
shRNA targeting viral transcripts could protect the transferred embryo by preventing 
infectious contamination within the uterine environment of the surrogate.  Ultimately, 
the potential exists to successfully create transgenic livestock for development of animal 
models for biomedical and pharmaceutical evaluation, and to increase production 
efficiency in a commercial setting by targeting gene expression in the early embryo. 
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APPENDIX A 
1X TE Buffer 
0.1579 g Tris-HCL (10mmol L
-1
) 
0.0038 g EDTA (0.1 mmol L
-1
) 
Q.S. 100 ml with ultrapure H2O 
 
Mix all until salts are dissolved and pH to 7.3 - 7.4, then filter through a 0.2 µm filter. 
Aliquot and store in -20ºC until use. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
106 
APPENDIX B 
 
50X TAE Buffer 
242 g Tris base (2 mol L
 -1
) 
57.1 ml glacial acetic acid (1 mol L
 -1
) 
100 ml 0.5 M Na2 EDTA (pH 8.0) 
Q.S. up to 1000 ml with ultrapure H2O 
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APPENDIX C 
 
2X Hepes Buffered Saline 
8.0 g NaCl 
0.37 g KCl 
0.099 g Na2HPO4 
1.0 g Dextrose 
5.0 g Hepes 
400 ml dd H20 
 
Mix  above thoroughly and pH to excatly 7.2.  Q.S. to 500 ml with dd H2O and filter 
sterilize. 
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APPENDIX D 
 
Protein Lysis Buffer 
1% v/v Triton X-100 
0.5% v/v NP-40 
150 mmol L
 -1
 NaCl 
10 mmol L
 -1
 EDTA 
1 mmol L
 -1
 EGTA 
0.2 mmol L
 -1
 Na3Vo4 
0.2 mmol L
 -1
 PMSF 
50 mmol L
 -1
 NaF 
30 mmol L
 -1
 Na4P2O7 
1 µg ml
 -1
 Leupeptin 
1 µg ml
 -1
 Pepstatin 
 
Mix all chemicals into desired volume of dd H2O, aliquot and store at -20ºC. 
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APPENDIX E 
 
4X Sample Buffer 
7.5 ml dH2O 
760 mg Tris-base 
2.0 g SDS 
Adjust pH to 7.0 
10 ml glycerol 
Adjust pH to 6.8 
5 ml 2-mercaptoethanol 
300 µl 2% bromphenol blue (in 100% ethanol) 
 
Aliquot and store at -20ºC.  
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APPENDIX F 
 
Polyacrlyamide Gel Formulation 
Reagent 10% Resolving Gel 5% Stacking Gel 
Water 3.6 ml 2.3 ml 
4X Separating Buffer
1
 2.0 ml 1.0 ml 
40% Acrylamide Bis* 2.0 ml 500 µl 
Ammonium Persulfate*
2
 400 µl 200 µl 
*Bio-Rad, Hercules, CA 
 
1
4X Separating Buffer 
18.16 g Tris-base 
0.4 g SDS 
200 µl TEMED 
75 ml dH2O 
Adjust pH to 8.8 then Q.S. to 100 ml with dH2O.  Aliquot in 4 ml and Store at -20ºC.  
 
2
Ammonium Persulfate (APS) 
100 mg APS 
1 ml dH2O 
Make fresh before casting each gel and protect from light. 
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APPENDIX G 
 
10X Electrode Buffer 
30.3 g Tris-base 
144.2 g glycine 
10.0 g DSD 
Adjust pH to 8.3 
Q.S. to 1 liter with dH2O 
Dilute 50 ml of 10X buffer into 450 ml dH2O for 1X working concentration. 
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APPENDIX H 
 
Tirs Buffered Saline with 0.05% Tween (TBST) 
2.42 g Tris-base 
800 ml dH2O 
Adjust pH to 7.5 
8.01 g NaCl 
500 µl Tween 20 
Q.S. to 1 liter with dH2O 
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APPENDIX I 
 
Stripping Buffer 
5.12 g Tris-HCl 
450 ml dH2O 
Adjust pH to 6.7 
3.9 ml β-meraptoethanol 
10 g SDS 
Q.S. to 500 ml 
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APPENDIX J 
 
Blocking Buffer 
0.1 g BSA (Do not use Fatty Acid Free) 
200 µl of serum (From same species as secondary antibody was raised in)  
9.8 ml DPBS 
 
Heat to 37ºC to melt BSA and store at 4ºC.  Centrifuge before use. 
 
 
115 
APPENDIX K 
 
Mounting Medium 
10 ml of 2X PBS-DABCO 
10 ml 40% Glycerol Solution 
4 µl ml
 -1
 Hoechst 44432 from 500 µg stock (Optional) 
Aliquot and store in dark amber tubes at 4 ºC. 
 
2X PBS-DABCO  
80 ml dH2O  
0.04 g KCl 
0.04 g KH2PO4 
1.60 g NaCl 
0.23 g Na2HPO4-H2O 
20.0 g DABCO 
Q.S. to 100 ml with dH2O, pH to 9.0 and filter sterilize and store at 4ºC. 
 
40% Glycerol Solution 
4 ml Glycerol 
6 ml dH2O  
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APPENDIX L 
 
Replicate 1 – Ct values from qPCR with transfected MDBK cells. 
Treatment 
Target 
Name Cт Cт Mean ∆Cт Mean  
Control E-cadherin 27.90323639  
Control E-cadherin 27.91489029  
Control E-cadherin 28.05664253 27.95825768 9.772618294  
Control GAPDH 18.13887787   
Control GAPDH 18.15245628  ∆Cт Mean 
Control GAPDH 18.26557922 18.18563843  AVERAGE 
Cy3-siRNA 1 E-cadherin 27.29890251 
Cy3-siRNA 1 E-cadherin 27.22384644 
Cy3-siRNA 1 E-cadherin 28.32833099 27.61702728 9.582667351 
Cy3-siRNA 1 GAPDH 17.96418762  
Cy3-siRNA 1 GAPDH 17.97932053  
Cy3-siRNA 1 GAPDH 18.15957069 18.03436089  9.395053 
Cy3-siRNA 2 E-cadherin 27.53307152  
Cy3-siRNA 2 E-cadherin 28.13148308  
Cy3-siRNA 2 E-cadherin 27.39345932 27.68600464 9.207438469  
Cy3-siRNA 2 GAPDH 18.39346695   
Cy3-siRNA 2 GAPDH 18.49491501   
Cy3-siRNA 2 GAPDH 18.5473156 18.47856522   
siEcad-12 E-cadherin 27.29037094  
siEcad-12 E-cadherin 29.43343925  
siEcad-12 E-cadherin 29.5652771 28.76303101 6.120476246  
siEcad-12 GAPDH 20.57524872   
siEcad-12 GAPDH 20.3726635   
siEcad-12 GAPDH 26.97974586 22.64255333   
siEcad-13 E-cadherin 30.7974987  
siEcad-13 E-cadherin 31.02691078  
siEcad-13 E-cadherin 30.76859665 30.86433601 11.00736237  
siEcad-13 GAPDH 19.67303085   
siEcad-13 GAPDH 19.98696518   
siEcad-13 GAPDH 19.910923 19.85697365   
siEcad-14 E-cadherin 28.12215424  
siEcad-14 E-cadherin 30.5201931  
siEcad-14 E-cadherin 28.35874367 29.0003643 10.16623974  
siEcad-14 GAPDH 18.78666496   
siEcad-14 GAPDH 18.86982727   
siEcad-14 GAPDH 18.8458786 18.83412361   
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Replicate 2 – Ct values from qPCR with transfected MDBK cells. 
Treatment Target Name Cт Cт Mean ∆Cт Mean  
Control E-cadherin 29.55807114  
Control E-cadherin 29.64612579  
Control E-cadherin 29.44480896 29.54966736 10.88727379  
Control GAPDH 18.75847054    
Control GAPDH 18.60272408   ∆Cт Mean 
Control GAPDH 18.62598991 18.66239357   AVERAGE 
Cy3-siRNA 1 E-cadherin 29.15526581 
Cy3-siRNA 1 E-cadherin 29.04409027 
Cy3-siRNA 1 E-cadherin 28.96968269 29.05634499 10.15249062 
Cy3-siRNA 1 GAPDH 18.82888222   
Cy3-siRNA 1 GAPDH 18.88990593   
Cy3-siRNA 1 GAPDH 18.99277878 18.90385437   10.14112 
Cy3-siRNA 2 E-cadherin 29.17858887   
Cy3-siRNA 2 E-cadherin 29.45907402   
Cy3-siRNA 2 E-cadherin 29.12443924 29.25403404 10.12975216   
Cy3-siRNA 2 GAPDH 19.12789536     
Cy3-siRNA 2 GAPDH 19.20157051     
Cy3-siRNA 2 GAPDH 19.04337883 19.12428093     
siEcad-12 E-cadherin 30.20763016  
siEcad-12 E-cadherin 30.85931969  
siEcad-12 E-cadherin 30.5081749 30.52503967 11.26663685  
siEcad-12 GAPDH 19.39923477    
siEcad-12 GAPDH 19.22440338    
siEcad-12 GAPDH 19.151577 19.25840569    
siEcad-13 E-cadherin 30.80695152  
siEcad-13 E-cadherin 30.64473534  
siEcad-13 E-cadherin 30.98952293 30.81373596 12.94279003  
siEcad-13 GAPDH 17.95928574    
siEcad-13 GAPDH 17.95530701    
siEcad-13 GAPDH 17.69824791 17.87094688    
siEcad-14 E-cadherin 28.78746605  
siEcad-14 E-cadherin 28.9896431  
siEcad-14 E-cadherin 29.82163239 29.19957924 11.43390751  
siEcad-14 GAPDH 17.9648819    
siEcad-14 GAPDH 17.83406067    
siEcad-14 GAPDH 17.49807739 17.76567268    
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Replicate 3 – Ct values from qPCR with transfected MDBK cells. 
Treatment Target Name Cт Cт Mean ∆Cт Mean  
Control E-cadherin 30.61294746  
Control E-cadherin 30.9888649  
Control E-cadherin 30.78809929 30.79663658 7.968657017  
Control GAPDH 22.67020798    
Control GAPDH 22.91531372   ∆Cт Mean 
Control GAPDH 22.89841843 22.82798004   AVERAGE 
Cy3-siRNA 1 E-cadherin 32.19010162 
Cy3-siRNA 1 E-cadherin 29.82148552 
Cy3-siRNA 1 E-cadherin 30.98059654 30.99739647 6.940715313 
Cy3-siRNA 1 GAPDH 23.765028   
Cy3-siRNA 1 GAPDH 24.20433807   
Cy3-siRNA 1 GAPDH 24.20067215 24.05667877   7.384953 
Cy3-siRNA 2 E-cadherin 30.11410332   
Cy3-siRNA 2 E-cadherin Undetermined   
Cy3-siRNA 2 E-cadherin Undetermined 30.11410332 7.829189777   
Cy3-siRNA 2 GAPDH 21.99886703     
Cy3-siRNA 2 GAPDH 22.38411522     
Cy3-siRNA 2 GAPDH 22.47175789 22.28491211     
siEcad-12 E-cadherin 31.97445297  
siEcad-12 E-cadherin 31.51188278  
siEcad-12 E-cadherin 31.48143005 31.65592194 9.329821587  
siEcad-12 GAPDH 22.66463661    
siEcad-12 GAPDH 21.6977787    
siEcad-12 GAPDH 22.61588669 22.3261013    
siEcad-13 E-cadherin 30.29426765  
siEcad-13 E-cadherin 30.3830986  
siEcad-13 E-cadherin 30.44544601 30.37426949 8.687010765  
siEcad-13 GAPDH 21.38614464    
siEcad-13 GAPDH 21.66250229    
siEcad-13 GAPDH 22.0131321 21.68726158    
siEcad-14 E-cadherin 29.70878029  
siEcad-14 E-cadherin 29.77229691  
siEcad-14 E-cadherin 29.98179817 29.82095909 8.845119476  
siEcad-14 GAPDH 20.94114494    
siEcad-14 GAPDH 20.95035934    
siEcad-14 GAPDH 21.03601265 20.97583961    
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APPENDIX M 
 
Density measurements and relative protein expression from three replicates of western 
blot analysis with MDBK transfected cells. 
 
  Average Density Ecad/GAPDH Relative Ecad Relative Ecad 
  E-cadherin GAPDH Ratio Expression 
Expression 
Average 
Control 1522 958 1.59 1.00 
  902 862 1.05 1 
  5527 1262 4.38 1 1 
Cy3-siRNA-1 1438 890 1.62 1.02 
  883 1420 0.62 0.59 
  4424 1215 3.64 0.83 
Cy3-siRNA-2 1373 1077 1.27 0.80 
  974 1314 0.74 0.71 
  4592 1203 3.82 0.87 0.80 
siEcad-12 273 621 0.44 0.28 
  197 1055 0.19 0.18 
  2104 1022 2.06 0.47 0.31 
siEcad-13 218 427 0.51 0.32 
  134 1191 0.11 0.11 
  1904 1141 1.67 0.38 0.27 
siEcad-14 332 581 0.57 0.36 
  176 1362 0.13 0.12 
  2033 1297 1.57 0.36 0.28 
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APPENDIX N 
 
Replicate 1 – Ct values from qPCR analysis with injected or transfected embryos. 
Treatment Target Name Cт Cт Mean ∆Cт Mean 
Control E-cadherin 31.49744034 
Control E-cadherin 31.7396965 
Control E-cadherin 31.94904137 31.72872353 3.536716461 
Control GAPDH 28.21177292   
Control GAPDH 27.9911232   
Control GAPDH 28.37313271 28.19201088   
Null-Inj E-cadherin 31.71483803 
Null-Inj E-cadherin 31.20245171 
Null-Inj E-cadherin 30.76796532 31.22841835 3.566733599 
Null-Inj GAPDH 27.47844124   
Null-Inj GAPDH 27.91827583   
Null-Inj GAPDH 27.58833694 27.66168404   
Ecad-Inj E-cadherin 34.94485092 
Ecad-Inj E-cadherin 34.85758972 
Ecad-Inj E-cadherin 34.38339233 34.72861099 2.8738029 
Ecad-Inj GAPDH 31.92241096   
Ecad-Inj GAPDH 31.95448112   
Ecad-Inj GAPDH 31.68753242 31.8548069   
Null-Trfx E-cadherin 31.96861649 
Null-Trfx E-cadherin 31.82393074 
Null-Trfx E-cadherin 31.10855865 31.63370323 3.689622879 
Null-Trfx GAPDH 27.9709816   
Null-Trfx GAPDH 27.95827866   
Null-Trfx GAPDH 27.90297699 27.94407845   
Ecad-Trfx E-cadherin 34.94418335 
Ecad-Trfx E-cadherin 34.63793564 
Ecad-Trfx E-cadherin 34.67087555 34.75099564 4.565057278 
Ecad-Trfx GAPDH 30.20593452   
Ecad-Trfx GAPDH 30.01963425   
Ecad-Trfx GAPDH 30.33225441 30.1859417   
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Replicate 2 – Ct values from qPCR analysis with injected or transfected embryos. 
Treatment Target Name Cт Cт Mean ∆Cт Mean 
Control E-cadherin 35.95948792 
Control E-cadherin 35.84313965 
Control E-cadherin 35.121521 35.64138412 3.521244049 
Control GAPDH 31.97899246  
Control GAPDH 31.96207428  
Control GAPDH 32.41934967 32.12013626   
Null-Inj E-cadherin 34.64260864 
Null-Inj E-cadherin 33.96315002 
Null-Inj E-cadherin 34.0406723 34.21547699 2.505097151 
Null-Inj GAPDH 31.73567772  
Null-Inj GAPDH 31.91873932  
Null-Inj GAPDH 31.47672272 31.71038055  
Ecad-Inj E-cadherin 34.13925171 
Ecad-Inj E-cadherin 35.05111694 
Ecad-Inj E-cadherin 34.40056229 34.53030777 3.029754639 
Ecad-Inj GAPDH 31.59681702  
Ecad-Inj GAPDH 31.53313637  
Ecad-Inj GAPDH 31.37171364 31.50055504  
Null-Trfx E-cadherin 34.34132385 
Null-Trfx E-cadherin 34.04854202 
Null-Trfx E-cadherin 33.99695969 34.12894058 3.822823286 
Null-Trfx GAPDH 29.82579231  
Null-Trfx GAPDH 30.53089142  
Null-Trfx GAPDH 30.56167221 30.30611992  
Ecad-Trfx E-cadherin 34.84516907 
Ecad-Trfx E-cadherin 35.08021545 
Ecad-Trfx E-cadherin 34.98668671 34.97069168 4.892755508 
Ecad-Trfx GAPDH 29.56757927  
Ecad-Trfx GAPDH 30.34253502  
Ecad-Trfx GAPDH 30.32369041 30.07793427   
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Replicate 3 – Ct values from qPCR analysis with injected or transfected embryos. 
Treatment Target Name Cт Cт Mean ∆Cт Mean 
Control E-cadherin 32.30030441 
Control E-cadherin 32.71348572 
Control E-cadherin 32.75072861 32.58817673 3.586159468 
Control GAPDH 28.9414978   
Control GAPDH 28.87763977   
Control GAPDH 29.186903 29.00201416   
Null-Inj E-cadherin 31.44138336 
Null-Inj E-cadherin 31.12998581 31.28568459 2.993611574 
Null-Inj GAPDH 28.2148304   
Null-Inj GAPDH 28.28322029   
Null-Inj GAPDH 28.37816811 28.2920742   
Null-Inj E-cadherin 31.28365326 
Ecad-Inj E-cadherin 31.27362633 
Ecad-Inj E-cadherin 30.86239624 31.13989258 2.94906044 
Ecad-Inj GAPDH 27.94904327   
Ecad-Inj GAPDH 28.56986809   
Ecad-Inj GAPDH 28.05358315 28.19083214   
Ecad-Inj E-cadherin 31.96383095 
Null-Trfx E-cadherin 32.51134491 
Null-Trfx E-cadherin 32.31225204 32.26247406 2.701194048 
Null-Trfx GAPDH 29.63020706   
Null-Trfx GAPDH 29.59121895   
Null-Trfx GAPDH 29.46241951 29.5612812   
Null-Trfx E-cadherin 33.42828751 
Ecad-Trfx E-cadherin 33.55495071 
Ecad-Trfx E-cadherin 33.85670471 33.61331177 3.926681519 
Ecad-Trfx GAPDH 30.18994141   
Ecad-Trfx GAPDH 29.7347393   
Ecad-Trfx GAPDH 29.13521767 29.68663216   
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